{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T23:08:11Z","timestamp":1794438491123,"version":"4.9.1"},"reference-count":289,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004156","name":"Mahidol University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004156","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"DOI":"10.1007\/s10238-025-01820-x","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T05:50:16Z","timestamp":1754286616000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Emerging CAR immunotherapies: broadening therapeutic horizons beyond cancer"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7521-4999","authenticated-orcid":false,"given":"Natthaporn","family":"Sueangoen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5218-0494","authenticated-orcid":false,"given":"Somsak","family":"Prasongtanakij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"1820_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1073\/pnas.90.2.720","volume":"90","author":"Z Eshhar","year":"1993","unstructured":"Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90:720\u20134. https:\/\/doi.org\/10.1073\/pnas.90.2.720.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1820_CR2","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86:10024\u20138. https:\/\/doi.org\/10.1073\/pnas.86.24.10024.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1820_CR3","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023;14:1188049. https:\/\/doi.org\/10.3389\/fimmu.2023.1188049.","journal-title":"Front Immunol"},{"key":"1820_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41571-023-00832-4","volume":"21","author":"SM Albelda","year":"2024","unstructured":"Albelda SM. CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn. Nat Rev Clin Oncol. 2024;21:47\u201366. https:\/\/doi.org\/10.1038\/s41571-023-00832-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"1820_CR5","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","volume":"20","author":"CL Flugel","year":"2023","unstructured":"Flugel CL, Majzner RG, Krenciute G, Dotti G, Riddell SR, Wagner DL, Abou-El-Enein M. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol. 2023;20:49\u201362. https:\/\/doi.org\/10.1038\/s41571-022-00704-3.","journal-title":"Nat Rev Clin Oncol"},{"key":"1820_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"key":"1820_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041003","author":"V Wang","year":"2023","unstructured":"Wang V, Gauthier M, Decot V, Reppel L, Bensoussan D. Systematic review on CAR-T cell clinical trials up to 2022: academic center input. Cancers (Basel). 2023. https:\/\/doi.org\/10.3390\/cancers15041003.","journal-title":"Cancers (Basel)"},{"key":"1820_CR8","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1158\/2643-3230.bcd-21-0084","volume":"2","author":"M Abou-El-Enein","year":"2021","unstructured":"Abou-El-Enein M, Elsallab M, Feldman SA, Fesnak AD, Heslop HE, Marks P, Till BG, Bauer G, Savoldo B. Scalable manufacturing of CAR T cells for cancer immunotherapy. Blood Cancer Discov. 2021;2:408\u201322. https:\/\/doi.org\/10.1158\/2643-3230.bcd-21-0084.","journal-title":"Blood Cancer Discov"},{"key":"1820_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/edbk_397912","volume":"43","author":"ERS Cliff","year":"2023","unstructured":"Cliff ERS, Kelkar AH, Russler-Germain DA, Tessema FA, Raymakers AJN, Feldman WB, Kesselheim AS. High cost of chimeric antigen receptor T-cells: challenges and solutions. Am Soc Clin Oncol Educ Book. 2023;43: e397912. https:\/\/doi.org\/10.1200\/edbk_397912.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"1820_CR10","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/bf00820666","volume":"18","author":"Z Eshhar","year":"1996","unstructured":"Eshhar Z, Bach N, Fitzer-Attas CJ, Gross G, Lustgarten J, Waks T, Schindler DG. The T-body approach: potential for cancer immunotherapy. Springer Semin Immunopathol. 1996;18:199\u2013209. https:\/\/doi.org\/10.1007\/bf00820666.","journal-title":"Springer Semin Immunopathol"},{"key":"1820_CR11","doi-asserted-by":"publisher","first-page":"6577","DOI":"10.4049\/jimmunol.151.11.6577","volume":"151","author":"I Stancovski","year":"1993","unstructured":"Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu\/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol. 1993;151:6577\u201382.","journal-title":"J Immunol"},{"key":"1820_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1084\/jem.178.1.361","volume":"178","author":"P Hwu","year":"1993","unstructured":"Hwu P, Shafer GE, Treisman J, Schindler DG, Gross G, Cowherd R, Rosenberg SA, Eshhar Z. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain. J Exp Med. 1993;178:361\u20136. https:\/\/doi.org\/10.1084\/jem.178.1.361.","journal-title":"J Exp Med"},{"key":"1820_CR13","doi-asserted-by":"publisher","first-page":"6106","DOI":"10.1158\/1078-0432.Ccr-06-1183","volume":"12","author":"MH Kershaw","year":"2006","unstructured":"Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106\u201315. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-06-1183.","journal-title":"Clin Cancer Res"},{"key":"1820_CR14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"DL Porter","year":"2011","unstructured":"Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1103849.","journal-title":"N Engl J Med"},{"key":"1820_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842","volume":"3","author":"M Kalos","year":"2011","unstructured":"Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3: 95ra73. https:\/\/doi.org\/10.1126\/scitranslmed.3002842.","journal-title":"Sci Transl Med"},{"key":"1820_CR16","doi-asserted-by":"publisher","unstructured":"Barros LRC, Couto SCF, da Silva Santurio D, Paix\u00e3o EA, Cardoso F, da Silva VJ, Klinger P, Ribeiro P, R\u00f3s FA, Oliveira TGM, et al: Systematic Review of Available CAR-T Cell Trials around the World. Cancers (Basel) 2022, 14. https:\/\/doi.org\/10.3390\/cancers14112667","DOI":"10.3390\/cancers14112667"},{"key":"1820_CR17","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","volume":"26","author":"CA Ramos","year":"2018","unstructured":"Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, Mehta B, Zhang H, Dakhova O, Carrum G, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin\u2019s lymphomas. Mol Ther. 2018;26:2727\u201337. https:\/\/doi.org\/10.1016\/j.ymthe.2018.09.009.","journal-title":"Mol Ther"},{"key":"1820_CR18","doi-asserted-by":"publisher","first-page":"6185","DOI":"10.1158\/1078-0432.Ccr-18-0426","volume":"24","author":"G Enblad","year":"2018","unstructured":"Enblad G, Karlsson H, Gammelg\u00e5rd G, Wenthe J, L\u00f6vgren T, Amini RM, Wikstrom KI, Essand M, Savoldo B, Hallb\u00f6\u00f6k H, et al. A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia. Clin Cancer Res. 2018;24:6185\u201394. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-18-0426.","journal-title":"Clin Cancer Res"},{"key":"1820_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-023-01470-0","volume":"16","author":"M-L Schubert","year":"2023","unstructured":"Schubert M-L, Schmitt A, H\u00fcckelhoven-Krauss A, Neuber B, Kunz A, Waldhoff P, Vonficht D, Yousefian S, Jopp-Saile L, Wang L, et al. Treatment of adult ALL patients with third-generation CD19-directed CAR T cells: results of a pivotal trial. J Hematol Oncol. 2023;16:79. https:\/\/doi.org\/10.1186\/s13045-023-01470-0.","journal-title":"J Hematol Oncol"},{"key":"1820_CR20","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1038\/mt.2013.192","volume":"21","author":"AA Hombach","year":"2013","unstructured":"Hombach AA, Rappl G, Abken H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 \u201csuper-stimulation.\u201d Mol Ther. 2013;21:2268\u201377. https:\/\/doi.org\/10.1038\/mt.2013.192.","journal-title":"Mol Ther"},{"key":"1820_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1158\/2326-6066.Cir-14-0200","volume":"3","author":"A K\u00fcnkele","year":"2015","unstructured":"K\u00fcnkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS, Jensen MC. Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas-FasL-dependent AICD. Cancer Immunol Res. 2015;3:368\u201379. https:\/\/doi.org\/10.1158\/2326-6066.Cir-14-0200.","journal-title":"Cancer Immunol Res"},{"key":"1820_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/imr.12125","volume":"257","author":"M Chmielewski","year":"2014","unstructured":"Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev. 2014;257:83\u201390. https:\/\/doi.org\/10.1111\/imr.12125.","journal-title":"Immunol Rev"},{"key":"1820_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.61","volume":"6","author":"M Cartellieri","year":"2016","unstructured":"Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, von Bonin M, Bejestani EP, Ehninger G, Bachmann MP. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016;6: e458. https:\/\/doi.org\/10.1038\/bcj.2016.61.","journal-title":"Blood Cancer J"},{"key":"1820_CR24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/ppo.0000000000000034","volume":"20","author":"HJ Pegram","year":"2014","unstructured":"Pegram HJ, Park JH, Brentjens RJ. CD28z CARs and armored CARs. Cancer J. 2014;20:127\u201333. https:\/\/doi.org\/10.1097\/ppo.0000000000000034.","journal-title":"Cancer J"},{"key":"1820_CR25","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","volume":"12","author":"G Agliardi","year":"2021","unstructured":"Agliardi G, Liuzzi AR, Hotblack A, De Feo D, N\u00fa\u00f1ez N, Stowe CL, Friebel E, Nannini F, Rindlisbacher L, Roberts TA, et al. Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma. Nat Commun. 2021;12:444. https:\/\/doi.org\/10.1038\/s41467-020-20599-x.","journal-title":"Nat Commun"},{"key":"1820_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.839783","volume":"13","author":"W Glienke","year":"2022","unstructured":"Glienke W, Dragon AC, Zimmermann K, Martyniszyn-Eiben A, Mertens M, Abken H, Rossig C, Altvater B, Aleksandrova K, Arseniev L, et al. GMP-Compliant Manufacturing of TRUCKs: CAR T Cells targeting GD(2) and Releasing Inducible IL-18. Front Immunol. 2022;13: 839783. https:\/\/doi.org\/10.3389\/fimmu.2022.839783.","journal-title":"Front Immunol"},{"key":"1820_CR27","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","volume":"15","author":"M Chmielewski","year":"2015","unstructured":"Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15:1145\u201354. https:\/\/doi.org\/10.1517\/14712598.2015.1046430.","journal-title":"Expert Opin Biol Ther"},{"key":"1820_CR28","doi-asserted-by":"publisher","first-page":"1386856","DOI":"10.3389\/fimmu.2024.1386856","volume":"15","author":"B Mart\u00edn-Antonio","year":"2024","unstructured":"Mart\u00edn-Antonio B, Blanco B, Gonz\u00e1lez-Murillo \u00c1, Hidalgo L, Minguill\u00f3n J, P\u00e9rez-Chac\u00f3n G. Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART consortium as a cooperative effort to overcome current limitations. Front Immunol. 2024;15:1386856. https:\/\/doi.org\/10.3389\/fimmu.2024.1386856.","journal-title":"Front Immunol"},{"key":"1820_CR29","doi-asserted-by":"publisher","first-page":"1034707","DOI":"10.3389\/fimmu.2022.103470730","volume":"13","author":"J Tomasik","year":"2022","unstructured":"Tomasik J, Jasi\u0144ski M, Basak GW. Next generations of CAR-T cells - new therapeutic opportunities in hematology? Front Immunol. 2022;13:1034707. https:\/\/doi.org\/10.3389\/fimmu.2022.103470730.","journal-title":"Front Immunol"},{"key":"1820_CR30","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.omto.2023.07.007","volume":"30","author":"B Xia","year":"2023","unstructured":"Xia B, Lin K, Wang X, Chen F, Zhou M, Li Y, Lin Y, Qiao Y, Li R, Zhang W, et al. Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment. Mol Ther Oncolytics. 2023;30:86\u2013102. https:\/\/doi.org\/10.1016\/j.omto.2023.07.007.","journal-title":"Mol Ther Oncolytics"},{"key":"1820_CR31","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1182\/blood.2024024861","volume":"145","author":"P Lu","year":"2025","unstructured":"Lu P, Zhang X, Yang J, Li J, Qiu L, Gong M, Wang H, Chen J, Liu H, Xiong M, et al. Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia. Blood. 2025;145:1022\u201333.","journal-title":"Blood"},{"key":"1820_CR32","doi-asserted-by":"publisher","unstructured":"Meeus F, Funeh CN, Awad RM, Zeven K, Autaers D, De Becker A, Van Riet I, Goyvaerts C, Tuyaerts S, Neyns B, et al: Preclinical evaluation of antigen-sensitive B7-H3-targeting nanobody-based CAR-T cells in glioblastoma cautions for on-target, off-tumor toxicity. J Immunother Cancer. https:\/\/doi.org\/10.1182\/blood.2024024861","DOI":"10.1182\/blood.2024024861"},{"key":"1820_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200892","volume":"32","author":"Z Duan","year":"2024","unstructured":"Duan Z, Li D, Li N, Lin S, Ren H, Hong J, Hinrichs CS, Ho M. CAR-T cells based on a TCR mimic nanobody targeting HPV16 E6 exhibit antitumor activity against cervical cancer. Mol Ther Oncol. 2024;32: 200892. https:\/\/doi.org\/10.1016\/j.omton.2024.200892.","journal-title":"Mol Ther Oncol"},{"key":"1820_CR34","doi-asserted-by":"publisher","first-page":"5920","DOI":"10.1038\/s41467-023-41631-w","volume":"14","author":"D Li","year":"2023","unstructured":"Li D, Wang R, Liang T, Ren H, Park C, Tai CH, Ni W, Zhou J, Mackay S, Edmondson E, et al. Camel nanobody-based B7\u2013H3 CAR-T cells show high efficacy against large solid tumours. Nat Commun. 2023;14:5920. https:\/\/doi.org\/10.1038\/s41467-023-41631-w.","journal-title":"Nat Commun"},{"key":"1820_CR35","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1126\/science.288.5466.669","volume":"288","author":"M Cavazzana-Calvo","year":"2000","unstructured":"Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, Selz F, Hue C, Certain S, Casanova JL, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science. 2000;288:669\u201372. https:\/\/doi.org\/10.1126\/science.288.5466.669.","journal-title":"Science"},{"key":"1820_CR36","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1089\/104303403322167993","volume":"14","author":"B Engels","year":"2003","unstructured":"Engels B, Cam H, Sch\u00fcler T, Indraccolo S, Gladow M, Baum C, Blankenstein T, Uckert W. Retroviral vectors for high-level transgene expression in T lymphocytes. Hum Gene Ther. 2003;14:1155\u201368. https:\/\/doi.org\/10.1089\/104303403322167993.","journal-title":"Hum Gene Ther"},{"key":"1820_CR37","doi-asserted-by":"publisher","DOI":"10.3390\/v13081528","author":"RP Labb\u00e9","year":"2021","unstructured":"Labb\u00e9 RP, Vessillier S, Rafiq QA. Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives. Viruses. 2021. https:\/\/doi.org\/10.3390\/v13081528.","journal-title":"Viruses"},{"key":"1820_CR38","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines4020009","author":"RA Morgan","year":"2016","unstructured":"Morgan RA, Boyerinas B. Genetic modification of T cells. Biomedicines. 2016. https:\/\/doi.org\/10.3390\/biomedicines4020009.","journal-title":"Biomedicines"},{"key":"1820_CR39","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","volume":"18","author":"D Wang","year":"2019","unstructured":"Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358\u201378. https:\/\/doi.org\/10.1038\/s41573-019-0012-9.","journal-title":"Nat Rev Drug Discov"},{"key":"1820_CR40","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41586-019-1054-1","volume":"568","author":"M Hamieh","year":"2019","unstructured":"Hamieh M, Dobrin A, Cabriolu A, van der Stegen SJC, Giavridis T, Mansilla-Soto J, Eyquem J, Zhao Z, Whitlock BM, Miele MM, et al. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape. Nature. 2019;568:112\u20136. https:\/\/doi.org\/10.1038\/s41586-019-1054-1.","journal-title":"Nature"},{"key":"1820_CR41","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/imr.12478","volume":"275","author":"JM Brady","year":"2017","unstructured":"Brady JM, Baltimore D, Balazs AB. Antibody gene transfer with adeno-associated viral vectors as a method for HIV prevention. Immunol Rev. 2017;275:324\u201333. https:\/\/doi.org\/10.1111\/imr.12478.","journal-title":"Immunol Rev"},{"key":"1820_CR42","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41408-021-00508-1","volume":"11","author":"W Nawaz","year":"2021","unstructured":"Nawaz W, Huang B, Xu S, Li Y, Zhu L, Yiqiao H, Wu Z, Wu X. AAV-mediated in vivo CAR gene therapy for targeting human T-cell leukemia. Blood Cancer J. 2021;11:119. https:\/\/doi.org\/10.1038\/s41408-021-00508-1.","journal-title":"Blood Cancer J"},{"key":"1820_CR43","unstructured":"AAV https:\/\/clinicaltrials.gov\/search?term=AAV&viewType=Table#classicRedirect. Accessed 11 March 2025"},{"key":"1820_CR44","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/mt.2016.11","volume":"24","author":"A Gogol-D\u00f6ring","year":"2016","unstructured":"Gogol-D\u00f6ring A, Ammar I, Gupta S, Bunse M, Miskey C, Chen W, Uckert W, Schulz TF, Izsv\u00e1k Z, Ivics Z. Genome-wide profiling reveals remarkable parallels between insertion site selection properties of the MLV retrovirus and the piggyBac transposon in primary human CD4(+) T cells. Mol Ther. 2016;24:592\u2013606. https:\/\/doi.org\/10.1038\/mt.2016.11.","journal-title":"Mol Ther"},{"key":"1820_CR45","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1006\/jmbi.2000.4047","volume":"302","author":"Z Izsv\u00e1k","year":"2000","unstructured":"Izsv\u00e1k Z, Ivics Z, Plasterk RH. Sleeping beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J Mol Biol. 2000;302:93\u2013102. https:\/\/doi.org\/10.1006\/jmbi.2000.4047.","journal-title":"J Mol Biol"},{"key":"1820_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.1","volume":"2","author":"N Sharma","year":"2013","unstructured":"Sharma N, Cai Y, Bak RO, Jakobsen MR, Schr\u00f8der LD, Mikkelsen JG. Efficient sleeping beauty DNA transposition from DNA minicircles. Mol Ther Nucleic Acids. 2013;2: e74. https:\/\/doi.org\/10.1038\/mtna.2013.1.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1820_CR47","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1089\/hum.2017.130","volume":"28","author":"R Hodge","year":"2017","unstructured":"Hodge R, Narayanavari SA, Izsv\u00e1k Z, Ivics Z. Wide awake and ready to move: 20 years of non-viral therapeutic genome engineering with the Sleeping Beauty transposon system. Hum Gene Ther. 2017;28:842\u201355. https:\/\/doi.org\/10.1089\/hum.2017.130.","journal-title":"Hum Gene Ther"},{"key":"1820_CR48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/blood-2005-05-2133","volume":"107","author":"X Huang","year":"2006","unstructured":"Huang X, Wilber AC, Bao L, Tuong D, Tolar J, Orchard PJ, Levine BL, June CH, McIvor RS, Blazar BR, Zhou X. Stable gene transfer and expression in human primary T cells by the Sleeping Beauty transposon system. Blood. 2006;107:483\u201391. https:\/\/doi.org\/10.1182\/blood-2005-05-2133.","journal-title":"Blood"},{"key":"1820_CR49","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1158\/0008-5472.Can-07-5600","volume":"68","author":"H Singh","year":"2008","unstructured":"Singh H, Manuri PR, Olivares S, Dara N, Dawson MJ, Huls H, Hackett PB, Kohn DB, Shpall EJ, Champlin RE, Cooper LJ. Redirecting specificity of T-cell populations for CD19 using the sleeping beauty system. Cancer Res. 2008;68:2961\u201371. https:\/\/doi.org\/10.1158\/0008-5472.Can-07-5600.","journal-title":"Cancer Res"},{"key":"1820_CR50","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1172\/jci86721","volume":"126","author":"P Kebriaei","year":"2016","unstructured":"Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, et al. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016;126:3363\u201376. https:\/\/doi.org\/10.1172\/jci86721.","journal-title":"J Clin Invest"},{"key":"1820_CR51","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1182\/blood.V130.Suppl_1.2059.2059","volume":"130","author":"P Kebriaei","year":"2017","unstructured":"Kebriaei P, Huls H, Olivares S, Orozco AF, Su S, Maiti SN, De Groot E, Smith A, Yang Y, Rondon G, et al. Long term follow up after adoptive transfer of CD19-Specific CAR+ T cells genetically modified via non-viral sleeping beauty s ystem following hematopoietic stem cell Transplantation (HSCT). Blood. 2017;130:2059. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.2059.2059.","journal-title":"Blood"},{"key":"1820_CR52","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.1182\/blood-2019-130617","volume":"134","author":"T Chan","year":"2019","unstructured":"Chan T, Ma X, Carvajal-Borda F, Velez J, Plummer J, Shepard L, Shah RR, Sallman DA, Sabzevari H. Preclinical characterization of Prgn-3006 Ultracar-T\u2122 for the treatment of AML and MDS: non-viral, multigenic autologous CAR-T cells administered one day after gene transfer. Blood. 2019;134:2660\u2013660. https:\/\/doi.org\/10.1182\/blood-2019-130617.","journal-title":"Blood"},{"key":"1820_CR53","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.1158\/1538-7445.Am2020-6593","volume":"80","author":"T Chan","year":"2020","unstructured":"Chan T, Chakiath M, Shepard L, Metenou S, Carvajal-Borda F, Velez J, Govekung A, Plummer J, Poortman C, Kamineny P, et al. Abstract 6593: PRGN-3005 UltraCAR-T\u2122: multigenic CAR-T cells generated using non-viral gene delivery and rapid manufacturing process for the treatment of ovarian cancer. Can Res. 2020;80:6593\u2013593. https:\/\/doi.org\/10.1158\/1538-7445.Am2020-6593.","journal-title":"Can Res"},{"key":"1820_CR54","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41434-021-00254-w","volume":"28","author":"S Prommersberger","year":"2021","unstructured":"Prommersberger S, Reiser M, Beckmann J, Danhof S, Amberger M, Quade-Lyssy P, Einsele H, Hudecek M, Bonig H, Ivics Z. Caramba: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. Gene Ther. 2021;28:560\u201371. https:\/\/doi.org\/10.1038\/s41434-021-00254-w.","journal-title":"Gene Ther"},{"key":"1820_CR55","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17128-1","volume":"11","author":"Q Chen","year":"2020","unstructured":"Chen Q, Luo W, Veach RA, Hickman AB, Wilson MH, Dyda F. Structural basis of seamless excision and specific targeting by piggyBac transposase. Nat Commun. 2020;11: 3446. https:\/\/doi.org\/10.1038\/s41467-020-17128-1.","journal-title":"Nat Commun"},{"key":"1820_CR56","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.ymthe.2018.05.007","volume":"26","author":"DC Bishop","year":"2018","unstructured":"Bishop DC, Xu N, Tse B, O\u2019Brien TA, Gottlieb DJ, Dolnikov A, Micklethwaite KP. Piggybac-engineered T cells expressing CD19-specific CARs that lack IgG1 Fc spacers have potent activity against B-ALL xenografts. Mol Ther. 2018;26:1883\u201395. https:\/\/doi.org\/10.1016\/j.ymthe.2018.05.007.","journal-title":"Mol Ther"},{"key":"1820_CR57","doi-asserted-by":"publisher","first-page":"120","DOI":"10.3978\/j.issn.2218-6751.2016.01.05","volume":"5","author":"S Zhao","year":"2016","unstructured":"Zhao S, Jiang E, Chen S, Gu Y, Shangguan AJ, Lv T, Luo L, Yu Z. Piggybac transposon vectors: the tools of the human gene encoding. Transl Lung Cancer Res. 2016;5:120\u20135. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2016.01.05.","journal-title":"Transl Lung Cancer Res"},{"key":"1820_CR58","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.omtm.2021.08.006","volume":"23","author":"I Ka\u0161t\u00e1nkov\u00e1","year":"2021","unstructured":"Ka\u0161t\u00e1nkov\u00e1 I, \u0160tach M, \u017di\u017ekov\u00e1 H, Pt\u00e1\u010dkov\u00e1 P, \u0160milauerov\u00e1 K, Mucha M, \u0160roller V, Ot\u00e1hal P. Enzymatically produced piggyBac transposon vectors for efficient non-viral manufacturing of CD19-specific CAR T cells. Mol Ther Methods Clin Dev. 2021;23:119\u201327. https:\/\/doi.org\/10.1016\/j.omtm.2021.08.006.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1820_CR59","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jcyt.2017.10.001","volume":"20","author":"P Pt\u00e1\u010dkov\u00e1","year":"2018","unstructured":"Pt\u00e1\u010dkov\u00e1 P, Musil J, \u0160tach M, Lesn\u00fd P, N\u011bme\u010dkov\u00e1 \u0160, Kr\u00e1l V, F\u00e1bry M, Ot\u00e1hal P. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21. Cytotherapy. 2018;20:507\u201320. https:\/\/doi.org\/10.1016\/j.jcyt.2017.10.001.","journal-title":"Cytotherapy"},{"key":"1820_CR60","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1182\/blood.2021010858","volume":"138","author":"KP Micklethwaite","year":"2021","unstructured":"Micklethwaite KP, Gowrishankar K, Gloss BS, Li Z, Street JA, Moezzi L, Mach MA, Sutrave G, Clancy LE, Bishop DC, et al. Investigation of product-derived lymphoma following infusion of piggyBac-modified CD19 chimeric antigen receptor T cells. Blood. 2021;138:1391\u2013405. https:\/\/doi.org\/10.1182\/blood.2021010858.","journal-title":"Blood"},{"key":"1820_CR61","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1182\/blood-2021-150469","volume":"138","author":"N Nishio","year":"2021","unstructured":"Nishio N, Hanajiri R, Ishikawa Y, Murata M, Taniguchi R, Hamada M, Nishikawa E, Kawashima N, Narita A, Muramatsu H, Takahashi Y. A phase I study of CD19 chimeric antigen receptor-T cells generated by the PiggyBac transposon vector for acute lymphoblastic leukemia. Blood. 2021;138:3831\u2013831. https:\/\/doi.org\/10.1182\/blood-2021-150469.","journal-title":"Blood"},{"key":"1820_CR62","doi-asserted-by":"publisher","first-page":"3725","DOI":"10.1007\/s00432-021-03613-7","volume":"147","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang Z, Ding Y, Fang Y, Wang P, Chu W, Jin Z, Yang X, Wang J, Lou J, Qian Q. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggybac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients. J Cancer Res Clin Oncol. 2021;147:3725\u201334. https:\/\/doi.org\/10.1007\/s00432-021-03613-7.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1820_CR63","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1182\/blood-2021-151672","volume":"138","author":"C Costello","year":"2021","unstructured":"Costello C, Derman BA, Kocoglu MH, Deol A, Ali AA, Gregory T, Dholaria B, Berdeja JG, Cohen AD, Patel KK, et al. Clinical trials of BCMA-targeted CAR-T cells utilizing a novel non-viral transposon system. Blood. 2021;138:3858\u2013858. https:\/\/doi.org\/10.1182\/blood-2021-151672.","journal-title":"Blood"},{"key":"1820_CR64","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s13770-022-00515-8","volume":"20","author":"S Shin","year":"2023","unstructured":"Shin S, Lee P, Han J, Kim SN, Lim J, Park DH, Paik T, Min J, Park CG, Park W. Nanoparticle-based chimeric antigen receptor therapy for cancer immunotherapy. Tissue Eng Regen Med. 2023;20:371\u201387. https:\/\/doi.org\/10.1007\/s13770-022-00515-8.","journal-title":"Tissue Eng Regen Med"},{"key":"1820_CR65","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2021-145572","volume":"138","author":"S Mailankody","year":"2021","unstructured":"Mailankody S, Liedtke M, Sidana S, Matous JV, Chhabra S, Oluwole OO, Malik SA, Kumar S, Nath R, Anwer F, et al. Universal updated phase 1 data validates the feasibility of allogeneic anti-BCMA ALLO-715 therapy for relapsed\/refractory multiple myeloma. Blood. 2021;138:651. https:\/\/doi.org\/10.1182\/blood-2021-145572.","journal-title":"Blood"},{"key":"1820_CR66","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1182\/blood.V126.23.2046.2046","volume":"126","author":"W Qasim","year":"2015","unstructured":"Qasim W, Amrolia PJ, Samarasinghe S, Ghorashian S, Zhan H, Stafford S, Butler K, Ahsan G, Gilmour K, Adams S, et al. First clinical application of Talen engineered universal CAR19 T cells in B-ALL. Blood. 2015;126:2046. https:\/\/doi.org\/10.1182\/blood.V126.23.2046.2046.","journal-title":"Blood"},{"key":"1820_CR67","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1056\/NEJMra1800729","volume":"380","author":"MH Porteus","year":"2019","unstructured":"Porteus MH. A new class of medicines through DNA editing. N Engl J Med. 2019;380:947\u201359. https:\/\/doi.org\/10.1056\/NEJMra1800729.","journal-title":"N Engl J Med"},{"key":"1820_CR68","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s41587-022-01418-8","volume":"41","author":"BR Shy","year":"2023","unstructured":"Shy BR, Vykunta VS, Ha A, Talbot A, Roth TL, Nguyen DN, Pfeifer WG, Chen YY, Blaeschke F, Shifrut E, et al. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. Nat Biotechnol. 2023;41:521\u201331. https:\/\/doi.org\/10.1038\/s41587-022-01418-8.","journal-title":"Nat Biotechnol"},{"key":"1820_CR69","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20211530","author":"SA Oh","year":"2022","unstructured":"Oh SA, Senger K, Madireddi S, Akhmetzyanova I, Ishizuka IE, Tarighat S, Lo JH, Shaw D, Haley B, Rutz S. High-efficiency nonviral CRISPR\/Cas9-mediated gene editing of human T cells using plasmid donor DNA. J Exp Med. 2022. https:\/\/doi.org\/10.1084\/jem.20211530.","journal-title":"J Exp Med"},{"key":"1820_CR70","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41587-019-0325-6","volume":"38","author":"DN Nguyen","year":"2020","unstructured":"Nguyen DN, Roth TL, Li PJ, Chen PA, Apathy R, Mamedov MR, Vo LT, Tobin VR, Goodman D, Shifrut E, et al. Polymer-stabilized Cas9 nanoparticles and modified repair templates increase genome editing efficiency. Nat Biotechnol. 2020;38:44\u20139. https:\/\/doi.org\/10.1038\/s41587-019-0325-6.","journal-title":"Nat Biotechnol"},{"key":"1820_CR71","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41586-019-1323-z","volume":"571","author":"SE Klompe","year":"2019","unstructured":"Klompe SE, Vo PLH, Halpin-Healy TS, Sternberg SH. Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration. Nature. 2019;571:219\u201325. https:\/\/doi.org\/10.1038\/s41586-019-1323-z.","journal-title":"Nature"},{"key":"1820_CR72","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.53868","author":"A Kova\u010d","year":"2020","unstructured":"Kova\u010d A, Miskey C, Menzel M, Grueso E, Gogol-D\u00f6ring A, Ivics Z. RNA-guided retargeting of Sleeping Beauty transposition in human cells. Elife. 2020. https:\/\/doi.org\/10.7554\/eLife.53868.","journal-title":"Elife"},{"key":"1820_CR73","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"1820_CR74","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/ejh.14076","volume":"112","author":"AN Khan","year":"2024","unstructured":"Khan AN, Asija S, Pendhari J, Purwar R. CAR-T cell therapy in hematological malignancies: where are we now and where are we heading for? Eur J Haematol. 2024;112:6\u201318. https:\/\/doi.org\/10.1111\/ejh.14076.","journal-title":"Eur J Haematol"},{"key":"1820_CR75","unstructured":"FDA approves obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-obecabtagene-autoleucel-adults-relapsed-or-refractory-b-cell-precursor-acute. Accessed 16 January 2025"},{"key":"1820_CR76","unstructured":"FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma?utm_source=chatgpt.com. Accessed 25 May 2025"},{"key":"1820_CR77","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"1820_CR78","doi-asserted-by":"publisher","unstructured":"Amor\u00f3s-P\u00e9rez B, Rivas-Pardo B, G\u00f3mez Del Moral M, Subiza JL, Mart\u00ednez-Naves E: State of the Art in CAR-T Cell Therapy for Solid Tumors: Is There a Sweeter Future? Cells 2024, 13. https:\/\/doi.org\/10.3390\/cells13090725","DOI":"10.3390\/cells13090725"},{"key":"1820_CR79","unstructured":"Phase I Study of Intracranial Injection of T Cells Expressing HER2-specific Chimeric Antigen Receptors (CAR) in Subjects With HER2-Positive Tumors of the Central Nervous System (iCAR). (Center for C, Gene Therapy BCoM, The Methodist Hospital Research I eds.) 2015. https:\/\/clinicaltrials.gov\/study\/NCT02442297. Accessed 23 May 2025"},{"key":"1820_CR80","unstructured":"Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for Subjects With Advanced Sarcoma (HEROS). (Center for C, Gene Therapy BCoM, The Methodist Hospital Research I, Cancer Prevention Research Institute of T eds.); 2009. https:\/\/clinicaltrials.gov\/study\/NCT00902044. Accessed 23 May 2025"},{"key":"1820_CR81","unstructured":"A Phase 1 Cellular Immunotherapy Study of Intraventricularly Administered Autologous HER2-Targeted Chimeric Antigen Receptor (HER2-CAR) T Cells in Patients With Brain and\/or Leptomeningeal Metastases From HER2 Positive Cancers. (National Cancer I, California Institute for Regenerative M eds.); 2018. https:\/\/clinicaltrials.gov\/study\/NCT03696030. Accessed 24 May 2025"},{"key":"1820_CR82","unstructured":"Phase 1 Study of HER2-Specific CAR T Cell Locoregional Immunotherapy for HER2 Positive Recurrent\/Refractory Pediatric Central Nervous System Tumors. 2018. https:\/\/clinicaltrials.gov\/study\/NCT03500991. Accessed 24 May 2025"},{"key":"1820_CR83","unstructured":"A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT303-406) in Patients With Relapsed or Refractory HER2 Positive Solid Tumors. (Shanghai Zhongshan H ed.; 2020. https:\/\/clinicaltrials.gov\/study\/NCT04511871. Accessed 25 May 2025"},{"key":"1820_CR84","unstructured":"A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors. (The Methodist Hospital Research I ed.; 2018. https:\/\/clinicaltrials.gov\/study\/NCT03740256. Accessed 24 May 2025"},{"key":"1820_CR85","unstructured":"A Single-arm, Open, Exploratory Clinical Study Evaluating the Safety and Efficacy of EGFR\/B7H3 CAR-T in Patients With EGFR\/ B7H3-positive Advanced Solid Tumors (Lung and Triple-negative Breast Cancer). 2022. https:\/\/clinicaltrials.gov\/study\/NCT05341492. Accessed 24 May 2025"},{"key":"1820_CR86","unstructured":"CAR-T Targeting GPC3, Mesothelin, Claudin18.2, GUCY2C, B7-H3, PSCA, PSMA, MUC1, TGF\u03b2, HER2, Lewis-Y, AXL, or EGFR for Immunotherapy of Lung Cancer: Phase I Clinical Trial. (Hunan Zhaotai Yongren Medical Innovation Co L, Guangdong Zhaotai InVivo Biomedicine Co L eds.); 2017. https:\/\/clinicaltrials.gov\/study\/NCT03198052. Accessed 24 May 2025"},{"key":"1820_CR87","unstructured":"A Single-arm, Open-label, Phase I Study to Evaluate the Safety and Efficacy of CXCR5 Modified EGFR Chimeric Antigen Receptor Autologous T Cells in EGFR-positive Patients With Advanced Non-small Cell Lung Cancer. 2021. https:\/\/clinicaltrials.gov\/study\/NCT05060796. Accessed 24 May 2025"},{"key":"1820_CR88","unstructured":"Phase 1 Study of Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2\/IL-13R alpha2 CAR (E-SYNC) T Cells in Adult Participants With EGFRvIII+ Glioblastoma. (California Institute for Regenerative M, National Cancer I eds.); 2023. https:\/\/clinicaltrials.gov\/study\/NCT06186401. Accessed 24 May 2025"},{"key":"1820_CR89","unstructured":"Phase I Study to Evaluate Cellular Immunotherapy Using Memory-Enriched T Cells Lentivirally Transduced to Express a CS1-Targeting, Hinge-Optimized, 41BB-Costimulatory Chimeric Antigen Receptor and a Truncated EGFR Following Lymphodepleting Chemotherapy in Adult Patients With CS1+ Multiple Myeloma. (National Cancer I ed.; 2018. https:\/\/clinicaltrials.gov\/study\/NCT03710421. Accessed 24 May 2025"},{"key":"1820_CR90","unstructured":"A Seamless Phase 1\/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod\u2122 CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression. 2024. https:\/\/clinicaltrials.gov\/study\/NCT06682793. Accessed 24 May 2025"},{"key":"1820_CR91","unstructured":"Phase I Study of Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers. 2014. https:\/\/clinicaltrials.gov\/study\/NCT02159716. Accessed 24 May 2025"},{"key":"1820_CR92","unstructured":"Phase I Clinical Trial of Autologous Mesothelin Re-directed T Cells in Patients With Chemotherapy Refractory Metastatic Pancreatic Cancer. 2013. https:\/\/clinicaltrials.gov\/study\/NCT01897415"},{"key":"1820_CR93","doi-asserted-by":"publisher","unstructured":"Phase I Study of Human Chimeric Antigen Receptor Modified T Cells in Patients With Mesothelin Expressing Cancers. (National Institutes of H, Tmunity Therapeutics awosoKP eds.); 2017. https:\/\/doi.org\/10.1016\/j.ymthe.2019.07.015. Accessed 24 May 2025","DOI":"10.1016\/j.ymthe.2019.07.015"},{"key":"1820_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00364","volume":"8","author":"X Pang","year":"2018","unstructured":"Pang X, Li H, Guan F, Li X. Multiple roles of glycans in hematological malignancies. Front Oncol. 2018;8: 364. https:\/\/doi.org\/10.3389\/fonc.2018.00364.","journal-title":"Front Oncol"},{"key":"1820_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2020.188464","volume":"1875","author":"D Thomas","year":"2021","unstructured":"Thomas D, Rathinavel AK, Radhakrishnan P. Altered glycosylation in cancer: a promising target for biomarkers and therapeutics. Biochim Biophys Acta Rev Cancer. 2021;1875: 188464. https:\/\/doi.org\/10.1016\/j.bbcan.2020.188464.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1820_CR96","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1126\/science.6729450","volume":"224","author":"GF Springer","year":"1984","unstructured":"Springer GF. T and Tn, general carcinoma autoantigens. Science. 1984;224:1198\u2013206. https:\/\/doi.org\/10.1126\/science.6729450.","journal-title":"Science"},{"key":"1820_CR97","doi-asserted-by":"publisher","first-page":"3367","DOI":"10.1038\/s41467-022-31035-7","volume":"13","author":"A Heard","year":"2022","unstructured":"Heard A, Landmann JH, Hansen AR, Papadopolou A, Hsu YS, Selli ME, Warrington JM, Lattin J, Chang J, Ha H, et al. Antigen glycosylation regulates efficacy of CAR T cells targeting CD19. Nat Commun. 2022;13:3367. https:\/\/doi.org\/10.1038\/s41467-022-31035-7.","journal-title":"Nat Commun"},{"key":"1820_CR98","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/j.immuni.2016.05.014","volume":"44","author":"AD Posey Jr","year":"2016","unstructured":"Posey AD Jr, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, Stone JD, Madsen TD, Schreiber K, Haines KM, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity. 2016;44:1444\u201354. https:\/\/doi.org\/10.1016\/j.immuni.2016.05.014.","journal-title":"Immunity"},{"key":"1820_CR99","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1007\/s11684-021-0901-2","volume":"16","author":"P Safarzadeh Kozani","year":"2022","unstructured":"Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success? Front Med. 2022;16:322\u201338. https:\/\/doi.org\/10.1007\/s11684-021-0901-2.","journal-title":"Front Med"},{"key":"1820_CR100","doi-asserted-by":"publisher","DOI":"10.3390\/cells8091070","author":"M Yazdanifar","year":"2019","unstructured":"Yazdanifar M, Zhou R, Grover P, Williams C, Bose M, Moore LJ, Wu ST, Maher J, Dreau D, Mukherjee AP. Overcoming immunological resistance enhances the efficacy of a novel anti-tMUC1-CAR T cell treatment against pancreatic ductal adenocarcinoma. Cells. 2019. https:\/\/doi.org\/10.3390\/cells8091070.","journal-title":"Cells"},{"key":"1820_CR101","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"1820_CR102","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1146\/annurev.iy.02.040184.000535","volume":"2","author":"S Hakomori","year":"1984","unstructured":"Hakomori S. Tumor-associated carbohydrate antigens. Annu Rev Immunol. 1984;2:103\u201326. https:\/\/doi.org\/10.1146\/annurev.iy.02.040184.000535.","journal-title":"Annu Rev Immunol"},{"key":"1820_CR103","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1136\/gut.48.4.558","volume":"48","author":"ZW Zhu","year":"2001","unstructured":"Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, Kleeff J, B\u00fcchler MW. Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut. 2001;48:558\u201364. https:\/\/doi.org\/10.1136\/gut.48.4.558.","journal-title":"Gut"},{"key":"1820_CR104","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1369\/0022155420933709","volume":"68","author":"N Li","year":"2020","unstructured":"Li N, Spetz MR, Ho M. The role of Glypicans in cancer progression and therapy. J Histochem Cytochem. 2020;68:841\u201362. https:\/\/doi.org\/10.1369\/0022155420933709.","journal-title":"J Histochem Cytochem"},{"key":"1820_CR105","unstructured":"A Phase I Clinical Study of Chimeric Antigen Receptor T Cells Targeting Glypican-3 (CAR-GPC3 T Cells) in Patients With Advanced Hepatocellular Carcinoma. (NanJing PLAH, First Affiliated Hospital of Zhejiang U, RenJi H eds.); 2019. https:\/\/clinicaltrials.gov\/study\/NCT03884751. Accessed 25 May 2025"},{"key":"1820_CR106","unstructured":"A Phase I Clinical Study of 4th Generation Chimeric Antigen Receptor T Cells Targeting Glypican-3 ( CAR-GPC3 T Cells) in Patients With Advanced Hepatocellular Carcinoma. (Carsgen Therapeutics Co L ed.; 2019. https:\/\/clinicaltrials.gov\/study\/NCT03980288. Accessed 25 May 2025"},{"key":"1820_CR107","unstructured":"Clinical Study of Redirected Autologous T Cells With a GPC3-targeted Chimeric Antigen Receptor in Patients With Refractory Hepatocellular Carcinoma. Carsgen Therapeutics Co L ed.; 2017. https:\/\/clinicaltrials.gov\/study\/NCT03146234. Accessed 25 May 2025"},{"key":"1820_CR108","unstructured":"Autologous T Cells Redirected to GPC3 for Treating Patients With Advanced HCC. 2015. https:\/\/clinicaltrials.gov\/study\/NCT02395250. Accessed 25 May 2025"},{"key":"1820_CR109","unstructured":"Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells As Immunotherapy for Patients with Hepatocellular Carcinoma. (Center for C, Gene Therapy BCoM, The Methodist Hospital Research I, Cancer Prevention Research Institute of T eds.); 2016. . https:\/\/clinicaltrials.gov\/study\/NCT02905188. Accessed 25 May 2025"},{"key":"1820_CR110","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22126567","author":"W Chen","year":"2021","unstructured":"Chen W, Zhang Z, Zhang S, Zhu P, Ko JK, Yung KK. MUC1: structure, function, and clinic application in epithelial cancers. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22126567.","journal-title":"Int J Mol Sci"},{"key":"1820_CR111","unstructured":"Exploratory Clinical Study of PD-1 Knockout Targeting MUC1 CAR-T Cells (AJMUC1) in the Treatment of MUC1-positive Advanced Breast Cancer. (Guangzhou Anjie Biomedical Technology Co L ed.; 2022. https:\/\/clinicaltrials.gov\/study\/NCT05812326. Accessed 25 May 2025"},{"key":"1820_CR112","first-page":"440","volume":"46","author":"ZL Wu","year":"1986","unstructured":"Wu ZL, Schwartz E, Seeger R, Ladisch S. Expression of GD2 ganglioside by untreated primary human neuroblastomas. Cancer Res. 1986;46:440\u20133.","journal-title":"Cancer Res"},{"key":"1820_CR113","unstructured":"Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells (4SCAR-GD2) Targeting Refractory and\/or Recurrent Neuroblastoma. 2016. https:\/\/clinicaltrials.gov\/study\/NCT02765243. Accessed 25 May 2025"},{"key":"1820_CR114","unstructured":"A Cancer Research UK Phase I Trial of Anti-GD2 Chimeric Antigen Receptor (CAR) Transduced T-cells (1RG-CART) in Patients With Relapsed or Refractory Neuroblastoma. 2016. https:\/\/clinicaltrials.gov\/study\/NCT02761915. Accessed 25 May 2025"},{"key":"1820_CR115","unstructured":"A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors. 2014. https:\/\/clinicaltrials.gov\/study\/NCT02107963. Accessed 25 May 2025"},{"key":"1820_CR116","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1006\/mthe.2002.0611","volume":"5","author":"SG Deeks","year":"2002","unstructured":"Deeks SG, Wagner B, Anton PA, Mitsuyasu RT, Scadden DT, Huang C, Macken C, Richman DD, Christopherson C, June CH, et al. A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy. Mol Ther. 2002;5:788\u201397. https:\/\/doi.org\/10.1006\/mthe.2002.0611.","journal-title":"Mol Ther"},{"key":"1820_CR117","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.virol.2013.08.002","volume":"446","author":"GK Sahu","year":"2013","unstructured":"Sahu GK, Sango K, Selliah N, Ma Q, Skowron G, Junghans RP. Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells. Virology. 2013;446:268\u201375. https:\/\/doi.org\/10.1016\/j.virol.2013.08.002.","journal-title":"Virology"},{"key":"1820_CR118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006613","volume":"13","author":"RS Leibman","year":"2017","unstructured":"Leibman RS, Richardson MW, Ellebrecht CT, Maldini CR, Glover JA, Secreto AJ, Kulikovskaya I, Lacey SF, Akkina SR, Yi Y, et al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog. 2017;13: e1006613. https:\/\/doi.org\/10.1371\/journal.ppat.1006613.","journal-title":"PLoS Pathog"},{"key":"1820_CR119","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jcyt.2018.02.002","volume":"20","author":"RL Kruse","year":"2018","unstructured":"Kruse RL, Shum T, Tashiro H, Barzi M, Yi Z, Whitten-Bauer C, Legras X, Bissig-Choisat B, Garaigorta U, Gottschalk S, Bissig KD. HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy. 2018;20:697\u2013705. https:\/\/doi.org\/10.1016\/j.jcyt.2018.02.002.","journal-title":"Cytotherapy"},{"key":"1820_CR120","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.virol.2023.06.015","volume":"586","author":"G Guo","year":"2023","unstructured":"Guo G, He W, Zhou Z, Diao Y, Sui J, Li W. PreS1- targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice. Virology. 2023;586:23\u201334. https:\/\/doi.org\/10.1016\/j.virol.2023.06.015.","journal-title":"Virology"},{"key":"1820_CR121","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/gutjnl-2014-308316","volume":"65","author":"GA Sautto","year":"2016","unstructured":"Sautto GA, Wisskirchen K, Clementi N, Castelli M, Diotti RA, Graf J, Clementi M, Burioni R, Protzer U, Mancini N. Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut. 2016;65:512\u201323. https:\/\/doi.org\/10.1136\/gutjnl-2014-308316.","journal-title":"Gut"},{"key":"1820_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1394-x","volume":"16","author":"J Proff","year":"2018","unstructured":"Proff J, Brey CU, Ensser A, Holter W, Lehner M. Turning the tables on cytomegalovirus: targeting viral Fc receptors by CARs containing mutated CH2-CH3 IgG spacer domains. J Transl Med. 2018;16: 26. https:\/\/doi.org\/10.1186\/s12967-018-1394-x.","journal-title":"J Transl Med"},{"key":"1820_CR123","doi-asserted-by":"publisher","first-page":"4083","DOI":"10.1128\/jvi.02117-09","volume":"84","author":"F Full","year":"2010","unstructured":"Full F, Lehner M, Thonn V, Goetz G, Scholz B, Kaufmann KB, Mach M, Abken H, Holter W, Ensser A. T cells engineered with a cytomegalovirus-specific chimeric immunoreceptor. J Virol. 2010;84:4083\u20138. https:\/\/doi.org\/10.1128\/jvi.02117-09.","journal-title":"J Virol"},{"key":"1820_CR124","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2174\/1874357901307010028","volume":"7","author":"SJ Talbot","year":"2013","unstructured":"Talbot SJ, Blair NF, McGill N, Ligertwood Y, Dutia BM, Johannessen I. An influenza virus M2 protein specific chimeric antigen receptor modulates influenza A\/WSN\/33 H1N1 infection in vivo. Open Virol J. 2013;7:28\u201336. https:\/\/doi.org\/10.2174\/1874357901307010028.","journal-title":"Open Virol J"},{"key":"1820_CR125","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","volume":"9","author":"MM D'Aloia","year":"2018","unstructured":"D\u2019Aloia MM, Zizzari IG, Sacchetti B, Pierelli L, Alimandi M. CAR-T cells: the long and winding road to solid tumors. Cell Death Dis. 2018;9:282. https:\/\/doi.org\/10.1038\/s41419-018-0278-6.","journal-title":"Cell Death Dis"},{"key":"1820_CR126","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1073\/pnas.1312789111","volume":"111","author":"PR Kumaresan","year":"2014","unstructured":"Kumaresan PR, Manuri PR, Albert ND, Maiti S, Singh H, Mi T, Roszik J, Rabinovich B, Olivares S, Krishnamurthy J, et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc Natl Acad Sci U S A. 2014;111:10660\u20135. https:\/\/doi.org\/10.1073\/pnas.1312789111.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1820_CR127","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1126\/science.1221789","volume":"336","author":"ID Iliev","year":"2012","unstructured":"Iliev ID, Funari VA, Taylor KD, Nguyen Q, Reyes CN, Strom SP, Brown J, Becker CA, Fleshner PR, Dubinsky M, et al. Interactions between commensal fungi and the C-type lectin receptor Dectin-1 influence colitis. Science. 2012;336:1314\u20137. https:\/\/doi.org\/10.1126\/science.1221789.","journal-title":"Science"},{"key":"1820_CR128","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.3389\/fimmu.2018.02231","volume":"9","author":"DE Ward","year":"2018","unstructured":"Ward DE, Fay BL, Adejuwon A, Han H, Ma Z. Chimeric antigen receptors based on low affinity mutants of Fc\u03b5RI re-direct T cell specificity to cells expressing membrane IgE. Front Immunol. 2018;9:2231. https:\/\/doi.org\/10.3389\/fimmu.2018.02231.","journal-title":"Front Immunol"},{"key":"1820_CR129","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.3389\/fimmu.2017.01125","volume":"8","author":"J Skuljec","year":"2017","unstructured":"Skuljec J, Chmielewski M, Happle C, Habener A, Busse M, Abken H, Hansen G. Chimeric antigen receptor-redirected regulatory T cells suppress experimental allergic airway inflammation, a model of asthma. Front Immunol. 2017;8:1125. https:\/\/doi.org\/10.3389\/fimmu.2017.01125.","journal-title":"Front Immunol"},{"key":"1820_CR130","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, et al. Targeting cardiac fibrosis with engineered T cells. Nature. 2019;573:430\u20133. https:\/\/doi.org\/10.1038\/s41586-019-1546-z.","journal-title":"Nature"},{"key":"1820_CR131","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1016\/j.ymthe.2019.09.021","volume":"27","author":"RJ Vagnozzi","year":"2019","unstructured":"Vagnozzi RJ, Johansen AKZ, Molkentin JD. CARdiac immunotherapy: T cells engineered to treat the fibrotic heart. Mol Ther. 2019;27:1869\u201371. https:\/\/doi.org\/10.1016\/j.ymthe.2019.09.021.","journal-title":"Mol Ther"},{"key":"1820_CR132","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1056\/nejmcibr2201182","volume":"386","author":"SL Friedman","year":"2022","unstructured":"Friedman SL. Fighting cardiac fibrosis with CAR T cells. N Engl J Med. 2022;386:1576\u20138. https:\/\/doi.org\/10.1056\/nejmcibr2201182.","journal-title":"N Engl J Med"},{"key":"1820_CR133","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science. 2016;353:179\u201384. https:\/\/doi.org\/10.1126\/science.aaf6756.","journal-title":"Science"},{"key":"1820_CR134","doi-asserted-by":"publisher","first-page":"102289","DOI":"10.1016\/j.jaut.2019.05.017","volume":"103","author":"M Tenspolde","year":"2019","unstructured":"Tenspolde M, Zimmermann K, Weber LC, Hapke M, Lieber M, Dywicki J, Frenzel A, Hust M, Galla M, Buitrago-Molina LE, et al. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J Autoimmun. 2019;103:102289. https:\/\/doi.org\/10.1016\/j.jaut.2019.05.017.","journal-title":"J Autoimmun"},{"key":"1820_CR135","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1742-2094-9-112","volume":"9","author":"M Fransson","year":"2012","unstructured":"Fransson M, Piras E, Burman J, Nilsson B, Essand M, Lu B, Harris RA, Magnusson PU, Brittebo E, Loskog AS. CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J Neuroinflammation. 2012;9:112. https:\/\/doi.org\/10.1186\/1742-2094-9-112.","journal-title":"J Neuroinflammation"},{"key":"1820_CR136","unstructured":"Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG). 2019. https:\/\/clinicaltrials.gov\/study\/NCT04146051. Accessed 20 February 2025"},{"key":"1820_CR137","unstructured":"An Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With CD19+ B Cell Systemic Lupus Erythematosus (SLE). (RenJi H ed.; 2017). https:\/\/clinicaltrials.gov\/study\/NCT03030976. Accessed 20 February 2025"},{"key":"1820_CR138","unstructured":"Clinical Study of CD19\/CD20 tanCAR T Cells in Relapsed and\/or Refractory AQP4-IgG Seropositive Neuromyelitis Optica Spectrum Disorders (NMOSD). 2018. https:\/\/clinicaltrials.gov\/study\/NCT03605238. Accessed 20 February 2025"},{"key":"1820_CR139","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1267762","volume":"10","author":"CJ Requejo Cier","year":"2023","unstructured":"Requejo Cier CJ, Valentini N, Lamarche C. Unlocking the potential of Tregs: innovations in CAR technology. Front Mol Biosci. 2023;10: 1267762. https:\/\/doi.org\/10.3389\/fmolb.2023.1267762.","journal-title":"Front Mol Biosci"},{"key":"1820_CR140","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.tips.2024.07.005","volume":"45","author":"YR Li","year":"2024","unstructured":"Li YR, Lyu Z, Chen Y, Fang Y, Yang L. Frontiers in CAR-T cell therapy for autoimmune diseases. Trends Pharmacol Sci. 2024;45:839\u201357. https:\/\/doi.org\/10.1016\/j.tips.2024.07.005.","journal-title":"Trends Pharmacol Sci"},{"key":"1820_CR141","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.886546","volume":"13","author":"AN Khan","year":"2022","unstructured":"Khan AN, Chowdhury A, Karulkar A, Jaiswal AK, Banik A, Asija S, Purwar R. Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation. Front Immunol. 2022;13: 886546. https:\/\/doi.org\/10.3389\/fimmu.2022.886546.","journal-title":"Front Immunol"},{"key":"1820_CR142","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","volume":"18","author":"DL Wagner","year":"2021","unstructured":"Wagner DL, Fritsche E, Pulsipher MA, Ahmed N, Hamieh M, Hegde M, Ruella M, Savoldo B, Shah NN, Turtle CJ, et al. Immunogenicity of CAR T cells in cancer therapy. Nat Rev Clin Oncol. 2021;18:379\u201393. https:\/\/doi.org\/10.1038\/s41571-021-00476-2.","journal-title":"Nat Rev Clin Oncol"},{"key":"1820_CR143","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/ajco.13474","volume":"18","author":"S Prasongtanakij","year":"2022","unstructured":"Prasongtanakij S, Anurathapan U, Vanichapol T, Jittorntrum B, Atjanasuppat K, Pongpitcha P, Pakakasama S, Songdej D, Sirachainan N, Paisooksantivatana K, et al. Production and characterization of haploidentical CD19 CAR T cells: validated to induce a continuous complete remission in a patient with relapsed refractory B-cell ALL. Asia Pac J Clin Oncol. 2022;18:44\u201351. https:\/\/doi.org\/10.1111\/ajco.13474.","journal-title":"Asia Pac J Clin Oncol"},{"key":"1820_CR144","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s40364-022-00417-w","volume":"10","author":"M Mazinani","year":"2022","unstructured":"Mazinani M, Rahbarizadeh F. CAR-T cell potency: from structural elements to vector backbone components. Biomark Res. 2022;10:70. https:\/\/doi.org\/10.1186\/s40364-022-00417-w.","journal-title":"Biomark Res"},{"key":"1820_CR145","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.7150\/jca.30406","volume":"10","author":"Z Wang","year":"2019","unstructured":"Wang Z, Chen W, Zhang X, Cai Z, Huang W. A long way to the battlefront: CAR T cell therapy against solid cancers. J Cancer. 2019;10:3112\u201323. https:\/\/doi.org\/10.7150\/jca.30406.","journal-title":"J Cancer"},{"key":"1820_CR146","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40259-019-00354-5","volume":"33","author":"B Gorovits","year":"2019","unstructured":"Gorovits B, Koren E. Immunogenicity of chimeric antigen receptor T-cell therapeutics. BioDrugs. 2019;33:275\u201384. https:\/\/doi.org\/10.1007\/s40259-019-00354-5.","journal-title":"BioDrugs"},{"key":"1820_CR147","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01783-1","volume":"22","author":"S Huang","year":"2023","unstructured":"Huang S, Wang X, Wang Y, Wang Y, Fang C, Wang Y, Chen S, Chen R, Lei T, Zhang Y, et al. Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies. Mol Cancer. 2023;22: 80. https:\/\/doi.org\/10.1186\/s12943-023-01783-1.","journal-title":"Mol Cancer"},{"key":"1820_CR148","doi-asserted-by":"publisher","first-page":"7090","DOI":"10.7150\/thno.114257","volume":"15","author":"M Ijaz","year":"2025","unstructured":"Ijaz M, Tan Q, Yan Y, Zhang D, Chen Q, Zhang Y, Tu Y, Guo B. Overcoming barriers in glioblastoma: the potential of CAR T cell immunotherapy. Theranostics. 2025;15:7090\u2013126. https:\/\/doi.org\/10.7150\/thno.114257.","journal-title":"Theranostics"},{"key":"1820_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11: 69. https:\/\/doi.org\/10.1038\/s41408-021-00459-7.","journal-title":"Blood Cancer J"},{"key":"1820_CR150","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00697","volume":"10","author":"S Mardiana","year":"2020","unstructured":"Mardiana S, Gill S. CAR T cells for acute myeloid leukemia: state of the art and future directions. Front Oncol. 2020;10: 697. https:\/\/doi.org\/10.3389\/fonc.2020.00697.","journal-title":"Front Oncol"},{"key":"1820_CR151","doi-asserted-by":"publisher","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","volume":"105","author":"KC Straathof","year":"2005","unstructured":"Straathof KC, Pul\u00e8 MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, Heslop HE, Spencer DM, Rooney CM. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105:4247\u201354. https:\/\/doi.org\/10.1182\/blood-2004-11-4564.","journal-title":"Blood"},{"key":"1820_CR152","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/s41417-020-00284-3","volume":"28","author":"W Warda","year":"2021","unstructured":"Warda W, Da Rocha MN, Trad R, Haderbache R, Salma Y, Bouquet L, Roussel X, Nicod C, Deschamps M, Ferrand C. Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T cell therapy using the inducible caspase 9 suicide gene safety switch. Cancer Gene Ther. 2021;28:1365\u201375. https:\/\/doi.org\/10.1038\/s41417-020-00284-3.","journal-title":"Cancer Gene Ther"},{"key":"1820_CR153","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/ejh.14007","volume":"112","author":"S Prasongtanakij","year":"2024","unstructured":"Prasongtanakij S, Preedagasamzin S, Jittorntrum B, Anurathapan U, Puavilai T, Niparuck P, Chantrathammachart P, Piyajaroenkij T, Uaesoontrachoon K, Uchibori R, et al. Cytotoxicity and exhaustion markers of chimeric antigen receptor T cells targeting BCMA in multiple myeloma cell lines between patients and healthy donors. Eur J Haematol. 2024;112:248\u201356. https:\/\/doi.org\/10.1111\/ejh.14007.","journal-title":"Eur J Haematol"},{"key":"1820_CR154","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s41232-024-00329-2","volume":"44","author":"N Hosen","year":"2024","unstructured":"Hosen N. Identification of cancer-specific cell surface targets for CAR-T cell therapy. Inflamm Regen. 2024;44:17. https:\/\/doi.org\/10.1186\/s41232-024-00329-2.","journal-title":"Inflamm Regen"},{"key":"1820_CR155","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/bs9.0000000000000173","volume":"5","author":"JY Wang","year":"2023","unstructured":"Wang JY, Wang L. CAR-T cell therapy: where are we now, and where are we heading? Blood Sci. 2023;5:237\u201348. https:\/\/doi.org\/10.1097\/bs9.0000000000000173.","journal-title":"Blood Sci"},{"key":"1820_CR156","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.111239","volume":"126","author":"J Zhou","year":"2024","unstructured":"Zhou J, Shi F, Luo X, Lei B, Shi Z, Huang C, Zhang Y, Li X, Wang H, Li X-Y, He X. The persistence and antitumor efficacy of CAR-T cells are modulated by tonic signaling within the CDR. Int Immunopharmacol. 2024;126: 111239. https:\/\/doi.org\/10.1016\/j.intimp.2023.111239.","journal-title":"Int Immunopharmacol"},{"key":"1820_CR157","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1158\/2326-6066.cir-20-0451","volume":"9","author":"E Landoni","year":"2021","unstructured":"Landoni E, Fuc\u00e1 G, Wang J, Chirasani VR, Yao Z, Dukhovlinova E, Ferrone S, Savoldo B, Hong LK, Shou P, et al. Modifications to the framework regions eliminate chimeric antigen receptor tonic signaling. Cancer Immunol Res. 2021;9:441\u201353. https:\/\/doi.org\/10.1158\/2326-6066.cir-20-0451.","journal-title":"Cancer Immunol Res"},{"key":"1820_CR158","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03442-3","volume":"20","author":"T Kouro","year":"2022","unstructured":"Kouro T, Himuro H, Sasada T. Exhaustion of CAR T cells: potential causes and solutions. J Transl Med. 2022;20: 239. https:\/\/doi.org\/10.1186\/s12967-022-03442-3.","journal-title":"J Transl Med"},{"key":"1820_CR159","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1016\/j.ymthe.2019.04.010","volume":"27","author":"H Qin","year":"2019","unstructured":"Qin H, Edwards JP, Zaritskaya L, Gupta A, Mu CJ, Fry TJ, Hilbert DM, LaFleur DW. Chimeric antigen receptors incorporating D domains targeting CD123 direct potent mono- and bi-specific antitumor activity of T cells. Mol Ther. 2019;27:1262\u201374. https:\/\/doi.org\/10.1016\/j.ymthe.2019.04.010.","journal-title":"Mol Ther"},{"key":"1820_CR160","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41423-020-0470-3","volume":"17","author":"L Wu","year":"2020","unstructured":"Wu L, Wei Q, Brzostek J, Gascoigne NRJ. Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells. Cell Mol Immunol. 2020;17:600\u201312. https:\/\/doi.org\/10.1038\/s41423-020-0470-3.","journal-title":"Cell Mol Immunol"},{"key":"1820_CR161","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1158\/1535-7163.mct-17-1097","volume":"17","author":"A Ajina","year":"2018","unstructured":"Ajina A, Maher J. Strategies to address chimeric antigen receptor tonic signaling. Mol Cancer Ther. 2018;17:1795\u2013815. https:\/\/doi.org\/10.1158\/1535-7163.mct-17-1097.","journal-title":"Mol Cancer Ther"},{"key":"1820_CR162","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102931","volume":"58","author":"J Jayaraman","year":"2020","unstructured":"Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, Chen YY, Zhao W. CAR-T design: elements and their synergistic function. EBioMedicine. 2020;58: 102931. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102931.","journal-title":"EBioMedicine"},{"key":"1820_CR163","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2019","unstructured":"Guedan S, Calderon H, Posey AD Jr., Maus MV. Engineering and design of chimeric antigen receptors. Mol Ther Methods Clin Dev. 2019;12:145\u201356. https:\/\/doi.org\/10.1016\/j.omtm.2018.12.009.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1820_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1335424","volume":"15","author":"S Smirnov","year":"2024","unstructured":"Smirnov S, Mateikovich P, Samochernykh K, Shlyakhto E. Recent advances on CAR-T signaling pave the way for prolonged persistence and new modalities in clinic. Front Immunol. 2024;15: 1335424. https:\/\/doi.org\/10.3389\/fimmu.2024.1335424.","journal-title":"Front Immunol"},{"key":"1820_CR165","doi-asserted-by":"publisher","DOI":"10.1080\/21688370.2017.1373208","volume":"5","author":"T Takiishi","year":"2017","unstructured":"Takiishi T, Fenero CIM, C\u00e2mara NOS. Intestinal barrier and gut microbiota: shaping our immune responses throughout life. Tissue Barriers. 2017;5: e1373208. https:\/\/doi.org\/10.1080\/21688370.2017.1373208.","journal-title":"Tissue Barriers"},{"key":"1820_CR166","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s41392-022-00974-4","volume":"7","author":"K Hou","year":"2022","unstructured":"Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, Zhu D, Koya JB, Wei L, Li J, Chen ZS. Microbiota in health and diseases. Signal Transduct Target Ther. 2022;7:135. https:\/\/doi.org\/10.1038\/s41392-022-00974-4.","journal-title":"Signal Transduct Target Ther"},{"key":"1820_CR167","doi-asserted-by":"publisher","first-page":"326","DOI":"10.3322\/caac.21398","volume":"67","author":"AP Bhatt","year":"2017","unstructured":"Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin. 2017;67:326\u201344. https:\/\/doi.org\/10.3322\/caac.21398.","journal-title":"CA Cancer J Clin"},{"key":"1820_CR168","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010488","author":"A Sevcikova","year":"2022","unstructured":"Sevcikova A, Izoldova N, Stevurkova V, Kasperova B, Chovanec M, Ciernikova S, Mego M. The impact of the microbiome on resistance to cancer treatment with chemotherapeutic agents and immunotherapy. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23010488.","journal-title":"Int J Mol Sci"},{"key":"1820_CR169","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","volume":"28","author":"M Smith","year":"2022","unstructured":"Smith M, Dai A, Ghilardi G, Amelsberg KV, Devlin SM, Pajarillo R, Slingerland JB, Beghi S, Herrera PS, Giardina P, et al. Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. Nat Med. 2022;28:713\u201323. https:\/\/doi.org\/10.1038\/s41591-022-01702-9.","journal-title":"Nat Med"},{"key":"1820_CR170","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","volume":"29","author":"CK Stein-Thoeringer","year":"2023","unstructured":"Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, et al. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy. Nat Med. 2023;29:906\u201316. https:\/\/doi.org\/10.1038\/s41591-023-02234-6.","journal-title":"Nat Med"},{"key":"1820_CR171","doi-asserted-by":"publisher","first-page":"5313","DOI":"10.1038\/s41467-022-32960-3","volume":"13","author":"Y Hu","year":"2022","unstructured":"Hu Y, Li J, Ni F, Yang Z, Gui X, Bao Z, Zhao H, Wei G, Wang Y, Zhang M, et al. CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies. Nat Commun. 2022;13:5313. https:\/\/doi.org\/10.1038\/s41467-022-32960-3.","journal-title":"Nat Commun"},{"key":"1820_CR172","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/annonc\/mdz206","volume":"30","author":"A Elkrief","year":"2019","unstructured":"Elkrief A, Derosa L, Kroemer G, Zitvogel L, Routy B. The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor? Ann Oncol. 2019;30:1572\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdz206.","journal-title":"Ann Oncol"},{"key":"1820_CR173","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.Cd-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8:1219\u201326. https:\/\/doi.org\/10.1158\/2159-8290.Cd-18-0442.","journal-title":"Cancer Discov"},{"key":"1820_CR174","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","volume":"125","author":"SL Maude","year":"2015","unstructured":"Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017\u201323. https:\/\/doi.org\/10.1182\/blood-2014-12-580068.","journal-title":"Blood"},{"key":"1820_CR175","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N Engl J Med. 2016;375:2561\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1610497.","journal-title":"N Engl J Med"},{"key":"1820_CR176","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","volume":"15","author":"I Dagogo-Jack","year":"2018","unstructured":"Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81\u201394. https:\/\/doi.org\/10.1038\/nrclinonc.2017.166.","journal-title":"Nat Rev Clin Oncol"},{"key":"1820_CR177","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00333","volume":"10","author":"AE Vilgelm","year":"2019","unstructured":"Vilgelm AE, Richmond A. Chemokines modulate immune surveillance in tumorigenesis, metastasis, and response to immunotherapy. Front Immunol. 2019;10: 333. https:\/\/doi.org\/10.3389\/fimmu.2019.00333.","journal-title":"Front Immunol"},{"key":"1820_CR178","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.trecan.2017.09.006","volume":"3","author":"LL van der Woude","year":"2017","unstructured":"van der Woude LL, Gorris MAJ, Halilovic A, Figdor CG, de Vries IJM. Migrating into the tumor: a roadmap for T Cells. Trends Cancer. 2017;3:797\u2013808. https:\/\/doi.org\/10.1016\/j.trecan.2017.09.006.","journal-title":"Trends Cancer"},{"key":"1820_CR179","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/978-3-319-24932-2_5","volume":"890","author":"V Mittal","year":"2016","unstructured":"Mittal V, El Rayes T, Narula N, McGraw TE, Altorki NK, Barcellos-Hoff MH. The microenvironment of lung cancer and therapeutic implications. Adv Exp Med Biol. 2016;890:75\u2013110. https:\/\/doi.org\/10.1007\/978-3-319-24932-2_5.","journal-title":"Adv Exp Med Biol"},{"key":"1820_CR180","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.omto.2022.03.009","volume":"25","author":"LA Kankeu Fonkoua","year":"2022","unstructured":"Kankeu Fonkoua LA, Sirpilla O, Sakemura R, Siegler EL, Kenderian SS. CAR T cell therapy and the tumor microenvironment: current challenges and opportunities. Mol Ther Oncolytics. 2022;25:69\u201377. https:\/\/doi.org\/10.1016\/j.omto.2022.03.009.","journal-title":"Mol Ther Oncolytics"},{"key":"1820_CR181","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1158\/0008-5472.Can-12-0122","volume":"72","author":"MA Swartz","year":"2012","unstructured":"Swartz MA, Iida N, Roberts EW, Sangaletti S, Wong MH, Yull FE, Coussens LM, DeClerck YA. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res. 2012;72:2473\u201380. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-0122.","journal-title":"Cancer Res"},{"key":"1820_CR182","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","volume":"11","author":"D Kasakovski","year":"2018","unstructured":"Kasakovski D, Xu L, Li Y. T cell senescence and CAR-T cell exhaustion in hematological malignancies. J Hematol Oncol. 2018;11:91. https:\/\/doi.org\/10.1186\/s13045-018-0629-x.","journal-title":"J Hematol Oncol"},{"key":"1820_CR183","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/leu.2015.247","volume":"30","author":"D Sommermeyer","year":"2016","unstructured":"Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia. 2016;30:492\u2013500. https:\/\/doi.org\/10.1038\/leu.2015.247.","journal-title":"Leukemia"},{"key":"1820_CR184","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1111\/bjh.19117","volume":"203","author":"E Galli","year":"2023","unstructured":"Galli E, Bellesi S, Pansini I, Di Cesare G, Iacovelli C, Malafronte R, Maiolo E, Chiusolo P, Sica S, Sor\u00e0 F, Hohaus S. The CD4\/CD8 ratio of infused CD19-CAR-T is a prognostic factor for efficacy and toxicity. Br J Haematol. 2023;203:564\u201370. https:\/\/doi.org\/10.1111\/bjh.19117.","journal-title":"Br J Haematol"},{"key":"1820_CR185","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15:47\u201362. https:\/\/doi.org\/10.1038\/nrclinonc.2017.148.","journal-title":"Nat Rev Clin Oncol"},{"key":"1820_CR186","doi-asserted-by":"publisher","first-page":"21","DOI":"10.6004\/jadpro.2019.10.4.11","volume":"10","author":"S Adkins","year":"2019","unstructured":"Adkins S. CAR T-cell therapy: adverse events and management. J Adv Pract Oncol. 2019;10:21\u20138. https:\/\/doi.org\/10.6004\/jadpro.2019.10.4.11.","journal-title":"J Adv Pract Oncol"},{"key":"1820_CR187","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","volume":"33","author":"EJM Grigor","year":"2019","unstructured":"Grigor EJM, Fergusson D, Kekre N, Montroy J, Atkins H, Seftel MD, Daugaard M, Presseau J, Thavorn K, Hutton B, et al. Risks and benefits of chimeric antigen receptor T-cell (CAR-T) therapy in cancer: a systematic review and meta-analysis. Transfus Med Rev. 2019;33:98\u2013110. https:\/\/doi.org\/10.1016\/j.tmrv.2019.01.005.","journal-title":"Transfus Med Rev"},{"key":"1820_CR188","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1097\/ccm.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45:e124\u201331. https:\/\/doi.org\/10.1097\/ccm.0000000000002053.","journal-title":"Crit Care Med"},{"key":"1820_CR189","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10555-024-10227-1","volume":"44","author":"AW Rankin","year":"2024","unstructured":"Rankin AW, Duncan BB, Allen C, Silbert SK, Shah NN. Evolving strategies for addressing CAR T-cell toxicities. Cancer Metastasis Rev. 2024;44:17. https:\/\/doi.org\/10.1007\/s10555-024-10227-1.","journal-title":"Cancer Metastasis Rev"},{"key":"1820_CR190","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1200\/jco.20.02477","volume":"39","author":"S Kadauke","year":"2021","unstructured":"Kadauke S, Myers RM, Li Y, Aplenc R, Baniewicz D, Barrett DM, Barz Leahy A, Callahan C, Dolan JG, Fitzgerald JC, et al. Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial. J Clin Oncol. 2021;39:920\u201330. https:\/\/doi.org\/10.1200\/jco.20.02477.","journal-title":"J Clin Oncol"},{"key":"1820_CR191","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745320","volume":"12","author":"PF Caimi","year":"2021","unstructured":"Caimi PF, Pacheco Sanchez G, Sharma A, Otegbeye F, Ahmed N, Rojas P, Patel S, Kleinsorge Block S, Schiavone J, Zamborsky K, et al. Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma. Front Immunol. 2021;12: 745320. https:\/\/doi.org\/10.3389\/fimmu.2021.745320.","journal-title":"Front Immunol"},{"key":"1820_CR192","unstructured":"FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous. Accessed 28 February 2025"},{"key":"1820_CR193","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00867-1","author":"C Gr\u00e9goire","year":"2024","unstructured":"Gr\u00e9goire C, Melenhorst JJ. Navigating CAR-T cell therapy long-term complications. Nat Cancer. 2024. https:\/\/doi.org\/10.1038\/s43018-024-00867-1.","journal-title":"Nat Cancer"},{"key":"1820_CR194","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","volume":"30","author":"G Ghilardi","year":"2024","unstructured":"Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrissette JJD, Caponetti GC, Paruzzo L, Harris JC, Chong EA, Susanibar Adaniya SP, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30:984\u20139. https:\/\/doi.org\/10.1038\/s41591-024-02826-w.","journal-title":"Nat Med"},{"key":"1820_CR195","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.Ccr-24-1798","volume":"30","author":"T Tix","year":"2024","unstructured":"Tix T, Alhomoud M, Shouval R, Cliff ERS, Perales MA. Cordas dos santos DM, Rejeski K: second primary malignancies after CAR T-Cell therapy: a systematic review and meta-analysis of 5,517 Lymphoma and myeloma patients. Clin Cancer Res. 2024;30:4690\u2013700. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-24-1798.","journal-title":"Clin Cancer Res"},{"key":"1820_CR196","unstructured":"FDA Requires Boxed Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies. https:\/\/www.fda.gov\/vaccines-blood-biologics\/safety-availability-biologics\/fda-requires-boxed-warning-t-cell-malignancies-following-treatment-bcma-directed-or-cd19-directed Accessed 28 February 2025"},{"key":"1820_CR197","doi-asserted-by":"publisher","first-page":"6939","DOI":"10.1056\/nejmoa2309728","volume":"142","author":"SJ Harrison","year":"2023","unstructured":"Harrison SJ, Nguyen T, Rahman M, Er J, Li J, Li K, Lendvai N, Schecter JM, Banerjee A, Roccia T, et al. CAR+ T-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood. 2023;142:6939. https:\/\/doi.org\/10.1056\/nejmoa2309728.","journal-title":"Blood"},{"key":"1820_CR198","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2023.100375","volume":"18","author":"H Balke-Want","year":"2023","unstructured":"Balke-Want H, Keerthi V, Cadinanos-Garai A, Fowler C, Gkitsas N, Brown AK, Tunuguntla R, Abou-El-Enein M, Feldman SA. Non-viral chimeric antigen receptor (CAR) T cells going viral. Immunooncol Technol. 2023;18: 100375. https:\/\/doi.org\/10.1016\/j.iotech.2023.100375.","journal-title":"Immunooncol Technol"},{"key":"1820_CR199","doi-asserted-by":"publisher","DOI":"10.3389\/fgeed.2020.613252","volume":"2","author":"G Blattner","year":"2020","unstructured":"Blattner G, Cavazza A, Thrasher AJ, Turchiano G. Gene editing and genotoxicity: targeting the off-targets. Front Genome Ed. 2020;2: 613252. https:\/\/doi.org\/10.3389\/fgeed.2020.613252.","journal-title":"Front Genome Ed"},{"key":"1820_CR200","unstructured":"Long Term Follow-up After Administration of Human Gene Therapy Products. Guidance for Industry https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/long-term-follow-after-administration-human-gene-therapy-products. Accessed 25 May 2025"},{"key":"1820_CR201","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23:90\u2013105. https:\/\/doi.org\/10.1038\/s41577-022-00732-1.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"1820_CR202","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1): 119. https:\/\/doi.org\/10.1186\/s13046-022-02327-z.","journal-title":"J Exp Clin Cancer Res"},{"key":"1820_CR203","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2017.226","volume":"32","author":"E Liu","year":"2018","unstructured":"Liu E, Tong Y, Dotti G, Shaim H, Savoldo B, Mukherjee M, Orange J, Wan X, Lu X, Reynolds A, et al. Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity. Leukemia. 2018;32:520\u201331. https:\/\/doi.org\/10.1038\/leu.2017.226.","journal-title":"Leukemia"},{"key":"1820_CR204","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/d41586-024-00809-y","volume":"627","author":"S Mallapaty","year":"2024","unstructured":"Mallapaty S. Cutting-edge CAR-T cancer therapy is now made in India - at one-tenth the cost. Nature. 2024;627:709\u201310. https:\/\/doi.org\/10.1038\/d41586-024-00809-y.","journal-title":"Nature"},{"key":"1820_CR205","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/nejmoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Rivi\u00e8re I, Gonen M, Wang X, S\u00e9n\u00e9chal B, Curran KJ, Sauter C, Wang Y, Santomasso B, Mead E, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449\u201359. https:\/\/doi.org\/10.1056\/nejmoa1709919.","journal-title":"N Engl J Med"},{"key":"1820_CR206","doi-asserted-by":"publisher","first-page":"1166038","DOI":"10.1186\/s13046-022-02327-z","volume":"14","author":"MK Kilgour","year":"2023","unstructured":"Kilgour MK, Bastin DJ, Lee SH, Ardolino M, McComb S, Visram A. Advancements in CAR-NK therapy: lessons to be learned from CAR-T therapy. Front Immunol. 2023;14:1166038. https:\/\/doi.org\/10.1186\/s13046-022-02327-z.","journal-title":"Front Immunol"},{"key":"1820_CR207","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","volume":"59","author":"G Xie","year":"2020","unstructured":"Xie G, Dong H, Liang Y, Ham JD, Rizwan R, Chen J. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020;59: 102975. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102975.","journal-title":"EBioMedicine"},{"key":"1820_CR208","doi-asserted-by":"publisher","first-page":"266","DOI":"10.3389\/fimmu.2015.00266","volume":"6","author":"M Carlsten","year":"2015","unstructured":"Carlsten M, Childs RW. Genetic manipulation of NK Cells for cancer immunotherapy: techniques and clinical implications. Front Immunol. 2015;6:266. https:\/\/doi.org\/10.3389\/fimmu.2015.00266.","journal-title":"Front Immunol"},{"key":"1820_CR209","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3389\/fimmu.2020.00812","volume":"11","author":"A Pfefferle","year":"2020","unstructured":"Pfefferle A, Jacobs B, Haroun-Izquierdo A, Kveberg L, Sohlberg E, Malmberg KJ. Deciphering natural killer cell homeostasis. Front Immunol. 2020;11:812. https:\/\/doi.org\/10.3389\/fimmu.2020.00812.","journal-title":"Front Immunol"},{"key":"1820_CR210","doi-asserted-by":"publisher","first-page":"3873","DOI":"10.1182\/blood-2021-151520","volume":"138","author":"K Patel","year":"2021","unstructured":"Patel K, Bachanova V, Goodman AM, Pagel JM, Griffis K, Anderson M, Atwal S, Bickers C, Szabo P, Wong L, et al. Phase I study of FT516, an off-the-shelf iPSC-derived NK cell therapy, in combination with rituximab in patients with relapsed\/refractory B-cell lymphoma. Blood. 2021;138:3873. https:\/\/doi.org\/10.1182\/blood-2021-151520.","journal-title":"Blood"},{"key":"1820_CR211","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Liu J. Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Cell Death Discov. 2024;10:318. https:\/\/doi.org\/10.1038\/s41420-024-02077-1.","journal-title":"Cell Death Discov"},{"key":"1820_CR212","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/nejmoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382:545\u201353. https:\/\/doi.org\/10.1056\/nejmoa1910607.","journal-title":"N Engl J Med"},{"key":"1820_CR213","unstructured":"Clinical Study on the Safety and Efficacy of Anti-Mesothelin Car NK Cells With Epithelial Ovarian Cancer. 2018. https:\/\/clinicaltrials.gov\/study\/NCT03692637. Accessed 8 July 2025"},{"key":"1820_CR214","unstructured":"Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours. 2018. https:\/\/clinicaltrials.gov\/study\/NCT03415100. Accessed 8 July 2025"},{"key":"1820_CR215","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/ni.1841","volume":"11","author":"DI Godfrey","year":"2010","unstructured":"Godfrey DI, Stankovic S, Baxter AG. Raising the NKT cell family. Nat Immunol. 2010;11:197\u2013206. https:\/\/doi.org\/10.1038\/ni.1841.","journal-title":"Nat Immunol"},{"key":"1820_CR216","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1038\/s43018-024-00830-0","volume":"5","author":"X Zhou","year":"2024","unstructured":"Zhou X, Wang Y, Dou Z, Delfanti G, Tsahouridis O, Pellegry CM, Zingarelli M, Atassi G, Woodcock MG, Casorati G, et al. CAR-redirected natural killer T cells demonstrate superior antitumor activity to CAR-T cells through multimodal CD1d-dependent mechanisms. Nat Cancer. 2024;5:1607\u201321. https:\/\/doi.org\/10.1038\/s43018-024-00830-0.","journal-title":"Nat Cancer"},{"key":"1820_CR217","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood-2013-11-541235","volume":"124","author":"A Heczey","year":"2014","unstructured":"Heczey A, Liu D, Tian G, Courtney AN, Wei J, Marinova E, Gao X, Guo L, Yvon E, Hicks J, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy. Blood. 2014;124:2824\u201333. https:\/\/doi.org\/10.1182\/blood-2013-11-541235.","journal-title":"Blood"},{"key":"1820_CR218","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12935-023-02923-9","volume":"23","author":"K Hadiloo","year":"2023","unstructured":"Hadiloo K, Tahmasebi S, Esmaeilzadeh A. CAR-NKT cell therapy: a new promising paradigm of cancer immunotherapy. Cancer Cell Int. 2023;23:86. https:\/\/doi.org\/10.1186\/s12935-023-02923-9.","journal-title":"Cancer Cell Int"},{"key":"1820_CR219","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","volume":"26","author":"A Heczey","year":"2020","unstructured":"Heczey A, Courtney AN, Montalbano A, Robinson S, Liu K, Li M, Ghatwai N, Dakhova O, Liu B, Raveh-Sadka T, et al. Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis. Nat Med. 2020;26:1686\u201390. https:\/\/doi.org\/10.1038\/s41591-020-1074-2.","journal-title":"Nat Med"},{"key":"1820_CR220","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-024-02226-y","author":"YR Li","year":"2024","unstructured":"Li YR, Zhou Y, Yu J, Kim YJ, Li M, Lee D, Zhou K, Chen Y, Zhu Y, Wang YC, et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol. 2024. https:\/\/doi.org\/10.1038\/s41587-024-02226-y.","journal-title":"Nat Biotechnol"},{"key":"1820_CR221","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaf074","author":"R Hatae","year":"2025","unstructured":"Hatae R, Watchmaker PB, Yamamichi A, Kyewalabye K, Okada K, Phyu S, Goretsky Y, Haegelin J, Pineo-Cavanaugh P, Gallus M, et al. Comparative evaluation of CAR-expressing T-, NK-, NKT-cells, and macrophages in an immunocompetent mouse glioma model. Neuro-Oncol Adv. 2025. https:\/\/doi.org\/10.1093\/noajnl\/vdaf074.","journal-title":"Neuro-Oncol Adv"},{"key":"1820_CR222","unstructured":"GD2 Specific Chimeric Antigen Receptor (CAR) and Interleukin-15 Expressing Autologous Natural Killer T-cells to Treat Children with Neuroblastoma. (Center for C, Gene Therapy BCoM eds.); 2017. https:\/\/clinicaltrials.gov\/study\/NCT03294954. Accessed 8 July 2025"},{"key":"1820_CR223","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","volume":"29","author":"A Heczey","year":"2023","unstructured":"Heczey A, Xu X, Courtney AN, Tian G, Barragan GA, Guo L, Amador CM, Ghatwai N, Rathi P, Wood MS, et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat Med. 2023;29:1379\u201388. https:\/\/doi.org\/10.1038\/s41591-023-02363-y.","journal-title":"Nat Med"},{"key":"1820_CR224","unstructured":"A Phase I Clinical Study to Assess the Safety and Efficacy of CD70-targeted CAR-NKT in the Treatment of Relapsed or Metastatic Advanced Renal Cell Carcinoma. 2023. https:\/\/clinicaltrials.gov\/study\/NCT06010875?cond=kidney%20cancer&intr=CAR-T&rank=1. Accessed 9 July 2025"},{"issue":"1","key":"1820_CR225","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.174.1.139","volume":"174","author":"IG Schmidt-Wolf","year":"1991","unstructured":"Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174(1):139\u201349. https:\/\/doi.org\/10.1084\/jem.174.1.139.","journal-title":"J Exp Med"},{"key":"1820_CR226","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-03869-z","volume":"15","author":"F Ghanbari Sevari","year":"2024","unstructured":"Ghanbari Sevari F, Mehdizadeh A, Abbasi K, Hejazian SS, Raeisi M. Cytokine-induced killer cells: new insights for therapy of hematologic malignancies. Stem Cell Res Ther. 2024;15: 254. https:\/\/doi.org\/10.1186\/s13287-024-03869-z.","journal-title":"Stem Cell Res Ther"},{"key":"1820_CR227","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1182\/blood-2007-06-092817","volume":"112","author":"R Nishimura","year":"2008","unstructured":"Nishimura R, Baker J, Beilhack A, Zeiser R, Olson JA, Sega EI, Karimi M, Negrin RS. In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood. 2008;112:2563\u201374. https:\/\/doi.org\/10.1182\/blood-2007-06-092817.","journal-title":"Blood"},{"key":"1820_CR228","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1485817","volume":"16","author":"LM Moser","year":"2025","unstructured":"Moser LM, Heim C, Koschade SE, Wendel P, Bozkurt S, Harenkamp S, Kreyenberg H, Merker M, M\u00fcnch C, Gradhand E, et al. CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma. Front Immunol. 2025;16: 1485817. https:\/\/doi.org\/10.3389\/fimmu.2025.1485817.","journal-title":"Front Immunol"},{"key":"1820_CR229","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1172\/jci138473","volume":"130","author":"CF Magnani","year":"2020","unstructured":"Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, Matera G, Cabiati B, Buracchi C, Borleri G, et al. Sleeping beauty-engineered CAR T cells achieve antileukemic activity without severe toxicities. J Clin Invest. 2020;130:6021\u201333. https:\/\/doi.org\/10.1172\/jci138473.","journal-title":"J Clin Invest"},{"key":"1820_CR230","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1016\/j.ymthe.2020.05.021","volume":"28","author":"MC Rotiroti","year":"2020","unstructured":"Rotiroti MC, Buracchi C, Arcangeli S, Galimberti S, Valsecchi MG, Perriello VM, Rasko T, Alberti G, Magnani CF, Cappuzzello C, et al. Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system. Mol Ther. 2020;28:1974\u201386. https:\/\/doi.org\/10.1016\/j.ymthe.2020.05.021.","journal-title":"Mol Ther"},{"key":"1820_CR231","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.581468","volume":"11","author":"M Merker","year":"2020","unstructured":"Merker M, Wagner J, Kreyenberg H, Heim C, Moser LM, Wels WS, Bonig H, Ivics Z, Ullrich E, Klingebiel T, et al. ERBB2-CAR-engineered cytokine-induced killer cells exhibit both CAR-mediated and innate immunity against high-risk rhabdomyosarcoma. Front Immunol. 2020;11: 581468. https:\/\/doi.org\/10.3389\/fimmu.2020.581468.","journal-title":"Front Immunol"},{"key":"1820_CR232","doi-asserted-by":"publisher","first-page":"6321","DOI":"10.1158\/1078-0432.Ccr-20-0357","volume":"26","author":"V Leuci","year":"2020","unstructured":"Leuci V, Donini C, Grignani G, Rotolo R, Mesiano G, Fiorino E, Gammaitoni L, D\u2019Ambrosio L, Merlini A, Landoni E, et al. CSPG4-specific CAR.CIK lymphocytes as a novel therapy for the treatment of multiple soft-tissue sarcoma histotypes. Clin Cancer Res. 2020;26:6321\u201334. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-0357.","journal-title":"Clin Cancer Res"},{"key":"1820_CR233","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41408-025-01260-6","volume":"15","author":"F Lussana","year":"2025","unstructured":"Lussana F, Magnani CF, Galimberti S, Gritti G, Gaipa G, Belotti D, Cabiati B, Napolitano S, Ferrari S, Moretti A, et al. Donor-derived CARCIK-CD19 cells engineered with sleeping beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation. Blood Cancer J. 2025;15:54. https:\/\/doi.org\/10.1038\/s41408-025-01260-6.","journal-title":"Blood Cancer J"},{"key":"1820_CR234","unstructured":"Phase I\/II Trial to Determine the in Vivo Engraftment, Safety and Clinical Activity of Allogeneic CIK Cells Transduced With a Transposon CD19-chimeric Antigen Receptor (CARCIK-CD19) Gene in Adult and Pediatric Patients With Relapsed\/Refractory B-cell Non-Hodgkin Lymphoma. 2023. https:\/\/clinicaltrials.gov\/study\/NCT05869279?term=NCT05869279&rank=1. Accessed 9 July 2025"},{"key":"1820_CR235","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.1073\/pnas.131202998","volume":"98","author":"CA Janeway Jr","year":"2001","unstructured":"Janeway CA Jr. How the immune system works to protect the host from infection: a personal view. Proc Natl Acad Sci U S A. 2001;98:7461\u20138. https:\/\/doi.org\/10.1073\/pnas.131202998.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1820_CR236","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nri3384","volume":"13","author":"P Vantourout","year":"2013","unstructured":"Vantourout P, Hayday A. Six-of-the-best: unique contributions of \u03b3\u03b4 T cells to immunology. Nat Rev Immunol. 2013;13:88\u2013100. https:\/\/doi.org\/10.1038\/nri3384.","journal-title":"Nat Rev Immunol"},{"key":"1820_CR237","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","volume":"8","author":"Y Hu","year":"2023","unstructured":"Hu Y, Hu Q, Li Y, Lu L, Xiang Z, Yin Z, Kabelitz D, Wu Y. \u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy. Signal Transduct Target Ther. 2023;8:434. https:\/\/doi.org\/10.1038\/s41392-023-01653-8.","journal-title":"Signal Transduct Target Ther"},{"key":"1820_CR238","doi-asserted-by":"publisher","first-page":"1554541","DOI":"10.3389\/fimmu.2025.1554541","volume":"16","author":"L Wang","year":"2025","unstructured":"Wang L, Li J, Xuan Y, Zhang J, Wang X, Hu W, Xiu L. Prospects for \u03b3\u03b4 T cells and chimeric antigen receptor \u03b3\u03b4 T cells in cancer immunotherapy. Front Immunol. 2025;16:1554541. https:\/\/doi.org\/10.3389\/fimmu.2025.1554541.","journal-title":"Front Immunol"},{"key":"1820_CR239","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ymthe.2017.12.001","volume":"26","author":"A Capsomidis","year":"2018","unstructured":"Capsomidis A, Benthall G, Van Acker HH, Fisher J, Kramer AM, Abeln Z, Majani Y, Gileadi T, Wallace R, Gustafsson K, et al. Chimeric antigen receptor-engineered human gamma delta T cells: enhanced cytotoxicity with retention of cross presentation. Mol Ther. 2018;26:354\u201365. https:\/\/doi.org\/10.1016\/j.ymthe.2017.12.001.","journal-title":"Mol Ther"},{"key":"1820_CR240","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.3389\/fimmu.2020.01347","volume":"11","author":"M Rozenbaum","year":"2020","unstructured":"Rozenbaum M, Meir A, Aharony Y, Itzhaki O, Schachter J, Bank I, Jacoby E, Besser MJ. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia. Front Immunol. 2020;11:1347. https:\/\/doi.org\/10.3389\/fimmu.2020.01347.","journal-title":"Front Immunol"},{"key":"1820_CR241","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.1200\/JCO.2022.40.16_suppl.7509","volume":"40","author":"SS Neelapu","year":"2022","unstructured":"Neelapu SS, Hamadani M, Miklos DB, Holmes H, Hinkle J, Kennedy-Wilde J, Maller O, Weinstein M, Galimi F, Lai R, Stevens DA. A phase 1 study of ADI-001: Anti-CD20 CAR-engineered allogeneic gamma delta (\u03b3\u03b4) T cells in adults with B-cell malignancies. J Clin Oncol. 2022;40:7509\u20137509. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.7509.","journal-title":"J Clin Oncol"},{"key":"1820_CR242","doi-asserted-by":"publisher","unstructured":"Pal SK, Garmezy B, Budworth H, Du X, Green S, Nishimoto K, Kennedy-Wilde J, Aftab BT, Maltzman JD, Vosganian GS, Rini BI: A phase 1\/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor \u03b3\u03b4 T cell therapy, in relapsed or refractory (R\/R) clear cell renal cell carcinoma (ccRCC). Journal of Clinical Oncology 2025, 43:TPS4613-TPS4613. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.TPS4613","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS4613"},{"key":"1820_CR243","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133:775\u201387. https:\/\/doi.org\/10.1016\/j.cell.2008.05.009.","journal-title":"Cell"},{"key":"1820_CR244","doi-asserted-by":"publisher","unstructured":"Arjomandnejad M, Kopec AL, Keeler AM: CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10020287","DOI":"10.3390\/biomedicines10020287"},{"key":"1820_CR245","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.3389\/fimmu.2018.02359","volume":"9","author":"Q Zhang","year":"2018","unstructured":"Zhang Q, Lu W, Liang CL, Chen Y, Liu H, Qiu F, Dai Z. Chimeric antigen receptor (CAR) treg: a promising approach to inducing immunological tolerance. Front Immunol. 2018;9:2359. https:\/\/doi.org\/10.3389\/fimmu.2018.02359.","journal-title":"Front Immunol"},{"key":"1820_CR246","doi-asserted-by":"publisher","unstructured":"Imura Y, Ando M, Kondo T, Ito M, Yoshimura A: CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD. JCI Insight 2020, 5. https:\/\/doi.org\/10.1172\/jci.insight.136185","DOI":"10.1172\/jci.insight.136185"},{"key":"1820_CR247","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/jci82771","volume":"126","author":"KG MacDonald","year":"2016","unstructured":"MacDonald KG, Hoeppli RE, Huang Q, Gillies J, Luciani DS, Orban PC, Broady R, Levings MK. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J Clin Invest. 2016;126:1413\u201324. https:\/\/doi.org\/10.1172\/jci82771.","journal-title":"J Clin Invest"},{"key":"1820_CR248","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1182\/blood-2016-07-727834","volume":"129","author":"J Yoon","year":"2017","unstructured":"Yoon J, Schmidt A, Zhang AH, K\u00f6nigs C, Kim YC, Scott DW. FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII. Blood. 2017;129:238\u201345. https:\/\/doi.org\/10.1182\/blood-2016-07-727834.","journal-title":"Blood"},{"key":"1820_CR249","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.581433","volume":"11","author":"Z Mukhatayev","year":"2020","unstructured":"Mukhatayev Z, Dellacecca ER, Cosgrove C, Shivde R, Jaishankar D, Pontarolo-Maag K, Eby JM, Henning SW, Ostapchuk YO, Cedercreutz K, et al. Antigen specificity enhances disease control by tregs in vitiligo. Front Immunol. 2020;11: 581433. https:\/\/doi.org\/10.3389\/fimmu.2020.581433.","journal-title":"Front Immunol"},{"key":"1820_CR250","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1053\/j.gastro.2009.01.049","volume":"136","author":"E Elinav","year":"2009","unstructured":"Elinav E, Adam N, Waks T, Eshhar Z. Amelioration of colitis by genetically engineered murine regulatory T cells redirected by antigen-specific chimeric receptor. Gastroenterology. 2009;136:1721\u201331. https:\/\/doi.org\/10.1053\/j.gastro.2009.01.049.","journal-title":"Gastroenterology"},{"key":"1820_CR251","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/mt.2014.41","volume":"22","author":"D Blat","year":"2014","unstructured":"Blat D, Zigmond E, Alteber Z, Waks T, Eshhar Z. Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells. Mol Ther. 2014;22:1018\u201328. https:\/\/doi.org\/10.1038\/mt.2014.41.","journal-title":"Mol Ther"},{"key":"1820_CR252","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41421-022-00433-y","volume":"8","author":"S Chen","year":"2022","unstructured":"Chen S, Chen G, Xu F, Sun B, Chen X, Hu W, Li F, Syeda MZ, Chen H, Wu Y, et al. Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells. Cell Discov. 2022;8:80. https:\/\/doi.org\/10.1038\/s41421-022-00433-y.","journal-title":"Cell Discov"},{"key":"1820_CR253","doi-asserted-by":"publisher","unstructured":"Badalzadeh M, Mazinani M, Pourpak Z, Heidarnazhad H, Mortaz E, Moin M, Farazmand A: In Vitro Analysis of Nine MicroRNAs in CD8+ T Cells of Asthmatic Patients and the Effects of Two FDA-approved Drugs. Iran J Allergy Asthma Immunol 2019, 18:358\u2013368. https:\/\/doi.org\/10.18502\/ijaai.v18i4.1414","DOI":"10.18502\/ijaai.v18i4.1414"},{"key":"1820_CR254","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, Mansilla-Soto J, Boyer JA, Li X, Giavridis T, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583:127\u201332. https:\/\/doi.org\/10.1038\/s41586-020-2403-9.","journal-title":"Nature"},{"key":"1820_CR255","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. \u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399. https:\/\/doi.org\/10.1038\/s41573-019-0051-2.","journal-title":"Nat Rev Drug Discov"},{"key":"1820_CR256","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.ekir.2022.03.030","volume":"7","author":"K Schreeb","year":"2022","unstructured":"Schreeb K, Culme-Seymour E, Ridha E, Dumont C, Atkinson G, Hsu B, Reinke P. Study design: human leukocyte antigen class I molecule A(\u2217)02-chimeric antigen receptor regulatory T cells in renal transplantation. Kidney Int Rep. 2022;7:1258\u201367. https:\/\/doi.org\/10.1016\/j.ekir.2022.03.030.","journal-title":"Kidney Int Rep"},{"key":"1820_CR257","unstructured":"A Single-arm, Open-label, Multi-center, Phase I\/II Study Evaluating the Safety and Clinical Activity of QEL-001, an Autologous CAR T Regulatory Cell Treatment Targeting HLA-A2, in HLA-A2\/ A28neg Patients That Have Received an HLA-A2pos Liver Transplant. 2022. https:\/\/clinicaltrials.gov\/study\/NCT05234190?cond=hla%20modified&checkSpell=&rank=9. Accessed 9 July 2025"},{"key":"1820_CR258","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399\u2013416. https:\/\/doi.org\/10.1038\/nrclinonc.2016.217.","journal-title":"Nat Rev Clin Oncol"},{"key":"1820_CR259","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.immuni.2014.06.010","volume":"41","author":"R Noy","year":"2014","unstructured":"Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41:49\u201361. https:\/\/doi.org\/10.1016\/j.immuni.2014.06.010.","journal-title":"Immunity"},{"key":"1820_CR260","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.molmed.2018.03.006","volume":"24","author":"JL Guerriero","year":"2018","unstructured":"Guerriero JL. Macrophages: the road less traveled, changing anticancer therapy. Trends Mol Med. 2018;24:472\u201389. https:\/\/doi.org\/10.1016\/j.molmed.2018.03.006.","journal-title":"Trends Mol Med"},{"key":"1820_CR261","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1186\/s12967-023-04479-8","volume":"21","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhu X, Liu H, Wang C, Chen Y, Wang H, Fang Y, Wu X, Xu Y, Li C, et al. The application of HER2 and CD47 CAR-macrophage in ovarian cancer. J Transl Med. 2023;21:654. https:\/\/doi.org\/10.1186\/s12967-023-04479-8.","journal-title":"J Transl Med"},{"key":"1820_CR262","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, Schmierer M, Gabrusiewicz K, Anderson NR, Petty NE, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38:947\u201353. https:\/\/doi.org\/10.1038\/s41587-020-0462-y.","journal-title":"Nat Biotechnol"},{"key":"1820_CR263","doi-asserted-by":"publisher","unstructured":"Su S, Lei A, Wang X, Lu H, Wang S, Yang Y, Li N, Zhang Y, Zhang J: Induced CAR-Macrophages as a Novel Therapeutic Cell Type for Cancer Immune Cell Therapies. Cells 2022, 11. https:\/\/doi.org\/10.3390\/cells11101652","DOI":"10.3390\/cells11101652"},{"key":"1820_CR264","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","volume":"34","author":"JN Brudno","year":"2019","unstructured":"Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Rev. 2019;34:45\u201355. https:\/\/doi.org\/10.1016\/j.blre.2018.11.002.","journal-title":"Blood Rev"},{"key":"1820_CR265","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","volume":"12","author":"J Lu","year":"2024","unstructured":"Lu J, Ma Y, Li Q, Xu Y, Xue Y, Xu S. CAR Macrophages: a promising novel immunotherapy for solid tumors and beyond. Biomarker Research. 2024;12:86. https:\/\/doi.org\/10.1186\/s40364-024-00637-2.","journal-title":"Biomarker Research"},{"key":"1820_CR266","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101931","volume":"6","author":"T Look","year":"2025","unstructured":"Look T, Sankowski R, Bouzereau M, Fazio S, Sun M, Buck A, Binder N, Mastall M, Prisco F, Seehusen F, et al. CAR T cells, CAR NK cells, and CAR macrophages exhibit distinct traits in glioma models but are similarly enhanced when combined with cytokines. Cell Rep Med. 2025;6: 101931. https:\/\/doi.org\/10.1016\/j.xcrm.2025.101931.","journal-title":"Cell Rep Med"},{"key":"1820_CR267","doi-asserted-by":"publisher","unstructured":"Liu M, Liu J, Liang Z, Dai K, Gan J, Wang Q, Xu Y, Chen YH, Wan X: CAR-Macrophages and CAR-T Cells Synergistically Kill Tumor Cells In Vitro. Cells 2022, 11. https:\/\/doi.org\/10.3390\/cells11223692","DOI":"10.3390\/cells11223692"},{"key":"1820_CR268","doi-asserted-by":"publisher","unstructured":"Chen K, Liu ML, Wang JC, Fang S. 2024. CAR-macrophage versus CAR-T for solid tumors: The race between a rising star and a superstar. Biomol Biomed. https:\/\/doi.org\/10.17305\/bb.2023.9675","DOI":"10.17305\/bb.2023.9675"},{"key":"1820_CR269","doi-asserted-by":"publisher","unstructured":"Abdou Y, Dees EC, Mortimer JE, Pohlmann PR, Johnson ML, Maziarz RT, Specht JM, Yuan Y, Ueno NT, Angelos M, et al. 2023. A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors. Journal of Clinical Oncology. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.TPS2666","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS2666"},{"key":"1820_CR270","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1038\/s41591-025-03495-z","volume":"31","author":"KA Reiss","year":"2025","unstructured":"Reiss KA, Angelos MG, Dees EC, Yuan Y, Ueno NT, Pohlmann PR, Johnson ML, Chao J, Shestova O, Serody JS, et al. CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial. Nat Med. 2025;31:1171\u201382. https:\/\/doi.org\/10.1038\/s41591-025-03495-z.","journal-title":"Nat Med"},{"key":"1820_CR271","unstructured":"Cohort Study to Determine the Antitumor Activity of New CAR-macrophages in Breast Cancer Patients' Derived Organoids (CARMA). (Institut National de la Sant\u00e9 Et de la Recherche M\u00e9dicale F ed.; 2021. https:\/\/clinicaltrials.gov\/study\/NCT05007379?term=NCT05007379&rank=1. Accessed 9 July 2025"},{"key":"1820_CR272","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrep.2024.101741","volume":"39","author":"L Guan","year":"2024","unstructured":"Guan L, Wu S, Zhu Q, He X, Li X, Song G, Zhang L, Yin X. GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma. Biochem Biophys Rep. 2024;39: 101741. https:\/\/doi.org\/10.1016\/j.bbrep.2024.101741.","journal-title":"Biochem Biophys Rep"},{"key":"1820_CR273","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.1000054","volume":"7","author":"E Martin","year":"2009","unstructured":"Martin E, Treiner E, Duban L, Guerri L, Laude H, Toly C, Premel V, Devys A, Moura IC, Tilloy F, et al. Stepwise development of MAIT cells in mouse and human. PLoS Biol. 2009;7: e54. https:\/\/doi.org\/10.1371\/journal.pbio.1000054.","journal-title":"PLoS Biol"},{"key":"1820_CR274","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1182\/blood-2010-08-303339","volume":"117","author":"M Dusseaux","year":"2011","unstructured":"Dusseaux M, Martin E, Serriari N, P\u00e9guillet I, Premel V, Louis D, Milder M, Le Bourhis L, Soudais C, Treiner E, Lantz O. Human MAIT cells are xenobiotic-resistant, tissue-targeted, CD161hi IL-17-secreting T cells. Blood. 2011;117:1250\u20139. https:\/\/doi.org\/10.1182\/blood-2010-08-303339.","journal-title":"Blood"},{"key":"1820_CR275","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.ymthe.2022.11.019","volume":"31","author":"YR Li","year":"2023","unstructured":"Li YR, Zhou K, Wilson M, Kramer A, Zhu Y, Dawson N, Yang L. Mucosal-associated invariant T cells for cancer immunotherapy. Mol Ther. 2023;31:631\u201346. https:\/\/doi.org\/10.1016\/j.ymthe.2022.11.019.","journal-title":"Mol Ther"},{"key":"1820_CR276","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1016\/j.bulcan.2021.07.003","volume":"108","author":"A Bohineust","year":"2021","unstructured":"Bohineust A, Tourret M, Derivry L, Caillat-Zucman S. Mucosal-associated invariant T (MAIT) cells, a new source of universal immune cells for chimeric antigen receptor (CAR)-cell therapy. Bull Cancer. 2021;108:S92\u20135. https:\/\/doi.org\/10.1016\/j.bulcan.2021.07.003.","journal-title":"Bull Cancer"},{"key":"1820_CR277","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13391","volume":"100","author":"OJ Cheng","year":"2024","unstructured":"Cheng OJ, Lebish EJ, Jensen O, Jacenik D, Trivedi S, Cacioppo JG, Aub\u00e9 J, Beswick EJ, Leung DT. Mucosal-associated invariant T cells modulate innate immune cells and inhibit colon cancer growth. Scand J Immunol. 2024;100: e13391. https:\/\/doi.org\/10.1111\/sji.13391.","journal-title":"Scand J Immunol"},{"key":"1820_CR278","doi-asserted-by":"publisher","first-page":"1369236","DOI":"10.3389\/fimmu.2024.1369236","volume":"15","author":"M Yigit","year":"2024","unstructured":"Yigit M, Basoglu OF, Unutmaz D. Mucosal-associated invariant T cells in cancer: dual roles, complex interactions and therapeutic potential. Front Immunol. 2024;15:1369236. https:\/\/doi.org\/10.3389\/fimmu.2024.1369236.","journal-title":"Front Immunol"},{"key":"1820_CR279","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.4049\/jimmunol.2100856","volume":"209","author":"M Dogan","year":"2022","unstructured":"Dogan M, Karhan E, Kozhaya L, Placek L, Chen X, Yigit M, Unutmaz D. Engineering human MAIT cells with chimeric antigen receptors for cancer immunotherapy. J Immunol. 2022;209:1523\u201331. https:\/\/doi.org\/10.4049\/jimmunol.2100856.","journal-title":"J Immunol"},{"key":"1820_CR280","doi-asserted-by":"publisher","unstructured":"Talvard-Balland N, Lambert M, Chevalier MF, Minet N, Salou M, Tourret M, Bohineust A, Milo I, Parietti V, Yvorra T, et al. 2024. Human MAIT cells inhibit alloreactive T cell responses and protect against acute graft-versus-host disease. JCI Insight. https:\/\/doi.org\/10.1172\/jci.insight.166310","DOI":"10.1172\/jci.insight.166310"},{"key":"1820_CR281","doi-asserted-by":"publisher","first-page":"17372","DOI":"10.1073\/pnas.0608138103","volume":"103","author":"BL Levine","year":"2006","unstructured":"Levine BL, Humeau LM, Boyer J, MacGregor RR, Rebello T, Lu X, Binder GK, Slepushkin V, Lemiale F, Mascola JR, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A. 2006;103:17372\u20137. https:\/\/doi.org\/10.1073\/pnas.0608138103.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1820_CR282","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41591-024-03478-6","volume":"31","author":"JK Jadlowsky","year":"2025","unstructured":"Jadlowsky JK, Hexner EO, Marshall A, Grupp SA, Frey NV, Riley JL, Veloso E, McConville H, Rogal W, Czuczman C, et al. Long-term safety of lentiviral or gammaretroviral gene-modified T cell therapies. Nat Med. 2025;31:1134\u201344. https:\/\/doi.org\/10.1038\/s41591-024-03478-6.","journal-title":"Nat Med"},{"key":"1820_CR283","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/bs.mcb.2021.06.014","volume":"167","author":"N Watanabe","year":"2022","unstructured":"Watanabe N, McKenna MK. Generation of CAR T-cells using \u03b3-retroviral vector. Methods Cell Biol. 2022;167:171\u201383. https:\/\/doi.org\/10.1016\/bs.mcb.2021.06.014.","journal-title":"Methods Cell Biol"},{"key":"1820_CR284","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/leu.2016.180","volume":"31","author":"R Monjezi","year":"2017","unstructured":"Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, Einsele H, Ivics Z, Hudecek M. Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. Leukemia. 2017;31:186\u201394. https:\/\/doi.org\/10.1038\/leu.2016.180.","journal-title":"Leukemia"},{"key":"1820_CR285","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.omtm.2022.03.012","volume":"25","author":"G Sutrave","year":"2022","unstructured":"Sutrave G, Xu N, Tang TCY, Dolnikov A, Gloss B, Gottlieb DJ, Micklethwaite KP, Gowrishankar K. Characterizing piggyBat-a transposase for genetic modification of T cells. Mol Ther Methods Clin Dev. 2022;25:250\u201363. https:\/\/doi.org\/10.1016\/j.omtm.2022.03.012.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"1820_CR286","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.122683","volume":"348","author":"Y Metanat","year":"2024","unstructured":"Metanat Y, Viktor P, Amajd A, Kaur I, Hamed AM, Abed Al-Abadi NK, Alwan NH, Chaitanya M, Lakshmaiya N, Ghildiyal P, et al. The paths toward non-viral CAR-T cell manufacturing: a comprehensive review of state-of-the-art methods. Life Sci. 2024;348: 122683. https:\/\/doi.org\/10.1016\/j.lfs.2024.122683.","journal-title":"Life Sci"},{"key":"1820_CR287","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2174\/0115748928277331231218115402","volume":"19","author":"Y Liu","year":"2024","unstructured":"Liu Y, Peng C, Ahad F, Ali Zaidi SA, Muluh TA, Fu Q. Advanced strategies of CAR-T cell therapy in solid tumors and hematological malignancies. Recent Pat Anticancer Drug Discov. 2024;19:557\u201372. https:\/\/doi.org\/10.2174\/0115748928277331231218115402.","journal-title":"Recent Pat Anticancer Drug Discov"},{"key":"1820_CR288","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.apsb.2020.10.020","volume":"11","author":"H Dana","year":"2021","unstructured":"Dana H, Chalbatani GM, Jalali SA, Mirzaei HR, Grupp SA, Suarez ER, Rap\u00f4so C, Webster TJ. CAR-T cells: Early successes in blood cancer and challenges in solid tumors. Acta Pharm Sin B. 2021;11:1129\u201347. https:\/\/doi.org\/10.1016\/j.apsb.2020.10.020.","journal-title":"Acta Pharm Sin B"},{"key":"1820_CR289","doi-asserted-by":"publisher","first-page":"1019115","DOI":"10.3389\/fimmu.2022.1019115","volume":"13","author":"J Huang","year":"2022","unstructured":"Huang J, Huang X, Huang J. CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies. Front Immunol. 2022;13:1019115. https:\/\/doi.org\/10.3389\/fimmu.2022.1019115.","journal-title":"Front Immunol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01820-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-025-01820-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-025-01820-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T06:51:19Z","timestamp":1764917479000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-025-01820-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":289,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1820"],"URL":"https:\/\/doi.org\/10.1007\/s10238-025-01820-x","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]},"assertion":[{"value":"22 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"274"}}